Synergistic	O
activation	O
of	O
MAP	B-protein
kinase	I-protein
(	O
ERK1/2	B-protein
)	O
by	O
erythropoietin	B-protein
and	O
stem	B-protein
cell	I-protein
factor	I-protein
is	O
essential	O
for	O
expanded	O
erythropoiesis	O
.	O

Stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
work	O
synergistically	O
to	O
support	O
erythropoiesis	O
,	O
but	O
the	O
mechanism	O
for	O
this	O
synergism	O
is	O
unknown	O
.	O

By	O
using	O
purified	B-cell_line
human	I-cell_line
erythroid	I-cell_line
colony-forming	I-cell_line
cells	I-cell_line
(	O
ECFC	B-cell_line
)	O
,	O
we	O
have	O
found	O
that	O
SCF	B-protein
and	O
EPO	B-protein
synergistically	O
activate	O
MAP	B-protein
kinase	I-protein
(	O
MAPK	B-protein
,	O
ERK1/2	B-protein
)	O
,	O
which	O
correlates	O
with	O
the	O
cell	O
growth	O
and	O
thus	O
may	O
be	O
responsible	O
for	O
the	O
synergistic	O
effects	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
PD98059	O
and	O
wortmannin	O
,	O
inhibitors	O
of	O
MEK	B-protein
and	O
PI-3	B-protein
kinase	I-protein
,	O
respectively	O
,	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
MAPK	B-protein
and	O
also	O
the	O
cell	O
growth	O
,	O
further	O
supporting	O
this	O
conclusion	O
.	O

Wortmannin	O
only	O
inhibits	O
MAPK	B-protein
activation	O
induced	O
by	O
EPO	B-protein
but	O
not	O
that	O
by	O
SCF	B-protein
,	O
suggesting	O
that	O
SCF	B-protein
and	O
EPO	B-protein
may	O
activate	O
MAPK	B-protein
through	O
different	O
pathways	O
,	O
which	O
would	O
facilitate	O
synergy	O
.	O

Furthermore	O
,	O
EPO	B-protein
,	O
but	O
not	O
SCF	B-protein
,	O
led	O
to	O
activation	O
of	O
STAT5	B-protein
,	O
whereas	O
SCF	B-protein
and	O
wortmannin	O
had	O
no	O
effect	O
on	O
the	O
EPO	B-protein
-induced	O
STAT5	B-protein
activation	O
,	O
suggesting	O
that	O
STAT5	B-protein
is	O
not	O
involved	O
in	O
the	O
synergistic	O
action	O
of	O
SCF	B-protein
and	O
EPO	B-protein
.	O

Together	O
,	O
the	O
data	O
suggest	O
that	O
synergistic	O
activation	O
of	O
MAPK	B-protein
by	O
SCF	B-protein
and	O
EPO	B-protein
is	O
essential	O
for	O
expanded	O
erythropoiesis	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

RAPID	NULL
COMMUNICATION	NULL
Synergistic	NULL
Activation	NULL
of	NULL
MAP	NULL
Kinase	NULL
(	NULL
ERK1/2	NULL
)	NULL
by	NULL
Erythropoietin	NULL
and	NULL
Stem	NULL
Cell	NULL
Factor	NULL
Is	NULL
Essential	NULL
for	NULL
Expanded	NULL
Erythropoiesis	NULL
By	NULL
Xingwei	NULL
Sui	NULL
,	NULL
Sanford	NULL
B.	NULL
Krantz	NULL
,	NULL
Min	NULL
You	NULL
,	NULL
and	NULL
Zhizhuang	NULL
Zhao	NULL
Stem	NULL
cell	NULL
factor	NULL
(	NULL
SCF	NULL
)	NULL
and	NULL
erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
work	NULL
synergistically	NULL
to	NULL
support	NULL
erythropoiesis	NULL
,	NULL
but	NULL
the	NULL
mechanism	NULL
for	NULL
this	NULL
synergism	NULL
is	NULL
unknown	NULL
.	NULL

By	NULL
using	NULL
purified	NULL
human	NULL
erythroid	NULL
colony-forming	NULL
cells	NULL
(	NULL
ECFC	NULL
)	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
SCF	NULL
and	NULL
EPO	NULL
synergistically	NULL
activate	NULL
MAP	NULL
kinase	NULL
(	NULL
MAPK	NULL
,	NULL
ERK1/	NULL
2	NULL
)	NULL
,	NULL
which	NULL
correlates	NULL
with	NULL
the	NULL
cell	NULL
growth	NULL
and	NULL
thus	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
synergistic	NULL
effects	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
PD98059	NULL
and	NULL
wortmannin	NULL
,	NULL
inhibitors	NULL
of	NULL
MEK	NULL
and	NULL
PI-3	NULL
kinase	NULL
,	NULL
respectively	NULL
,	NULL
inhibited	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
and	NULL
also	NULL
the	NULL
cell	NULL
growth	NULL
,	NULL
further	NULL
supporting	NULL
this	NULL
conclusion	NULL
.	NULL

Wortmannin	NULL
only	NULL
inhibits	NULL
MAPK	NULL
activation	NULL
in	NULL
RYTHROPOIESIS	NULL
IS	NULL
REGULATED	NULL
by	NULL
a	NULL
number	NULL
of	NULL
growth	NULL
factors	NULL
and	NULL
cytokines	NULL
,	NULL
among	NULL
which	NULL
stem	NULL
cell	NULL
factor	NULL
(	NULL
SCF	NULL
)	NULL
and	NULL
erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
play	NULL
an	NULL
essential	NULL
role	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
.	NULL
'	NULL

''	NULL
Mice	NULL
with	NULL
mutations	NULL
in	NULL
the	NULL
SCF	NULL
gene	NULL
,	NULL
Steel	NULL
(	NULL
Sl	NULL
)	NULL
,	NULL
or	NULL
its	NULL
receptor	NULL
gene	NULL
c-kit	NULL
(	NULL
W	NULL
)	NULL
develop	NULL
severe	NULL
anemia	NULL
characterized	NULL
by	NULL
depressed	NULL
erythropoiesis*	NULL
``	NULL
;	NULL
EPO	NULL
and	NULL
EPO-receptor	NULL
(	NULL
EPO-R	NULL
)	NULL
knockout	NULL
mice	NULL
die	NULL
of	NULL
failure	NULL
of	NULL
fetal	NULL
liver	NULL
erythrocyte	NULL
generation	NULL
.	NULL
``	NULL

In	NULL
vitro	NULL
,	NULL
whereas	NULL
EPO	NULL
alone	NULL
is	NULL
able	NULL
to	NULL
produce	NULL
human	NULL
erythroid	NULL
cell	NULL
development	NULL
and	NULL
maturation	NULL
from	NULL
progenitor	NULL
cells	NULL
,	NULL
a	NULL
markedly	NULL
enhanced	NULL
,	NULL
synergistic	NULL
proliferation	NULL
and	NULL
expansion	NULL
of	NULL
developing	NULL
erythroid	NULL
cells	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
EPO	NULL
and	NULL
SCF	NULL
.	NULL

!	NULL

4-0	NULL
Although	NULL
the	NULL
synergistic	NULL
effects	NULL
of	NULL
EPO	NULL
and	NULL
SCF	NULL
on	NULL
the	NULL
production	NULL
of	NULL
erythroid	NULL
cells	NULL
have	NULL
been	NULL
well	NULL
documented	NULL
,	NULL
the	NULL
intracellular	NULL
mechanism	NULL
by	NULL
which	NULL
SCF	NULL
and	NULL
EPO	NULL
coordinate	NULL
the	NULL
synergistic	NULL
effect	NULL
is	NULL
poorly	NULL
understood	NULL
.	NULL

In	NULL
a	NULL
recent	NULL
study	NULL
,	NULL
Wu	NULL
et	NULL
al	NULL
``	NULL
reported	NULL
that	NULL
,	NULL
in	NULL
HCD57	NULL
cells	NULL
,	NULL
SCF	NULL
rapidly	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
and	NULL
c-Kit	NULL
physically	NULL
associates	NULL
with	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
EPO-R	NULL
.	NULL

They	NULL
proposed	NULL
that	NULL
c-Kit	NULL
activates	NULL
EPO-R	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
to	NULL
induce	NULL
further	NULL
proliferation	NULL
and	NULL
maturation	NULL
of	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

This	NULL
could	NULL
provide	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
synergistic	NULL
effect	NULL
of	NULL
EPO	NULL
and	NULL
SCF	NULL
on	NULL
erythropoiesis	NULL
.	NULL

However	NULL
,	NULL
HCD57	NULL
is	NULL
an	NULL
immortal	NULL
cell	NULL
line	NULL
that	NULL
does	NULL
not	NULL
exhibit	NULL
synergistic	NULL
cell	NULL
growth	NULL
upon	NULL
combined	NULL
treatment	NULL
with	NULL
SCF	NULL
and	NULL
EPO	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
we	NULL
From	NULL
the	NULL
Hematology	NULL
Division	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Department	NULL
of	NULL
Veterans	NULL
Affairs	NULL
Medical	NULL
Center	NULL
,	NULL
and	NULL
Vanderbilt	NULL
Cancer	NULL
Center	NULL
,	NULL
Vanderbilt	NULL
University	NULL
,	NULL
Nashville	NULL
,	NULL
TN	NULL
.	NULL

Submitted	NULL
March	NULL
17	NULL
,	NULL
1998	NULL
;	NULL
accepted	NULL
June	NULL
1	NULL
,	NULL
1998	NULL
.	NULL

Supported	NULL
by	NULL
a	NULL
Veterans	NULL
Health	NULL
Administration	NULL
Merit	NULL
Review	NULL
Grant	NULL
(	NULL
to	NULL
S.B.K	NULL
.	NULL
)	NULL

,	NULL
Granis	NULL
No	NULL
.	NULL

DK-15555	NULL
and	NULL
2	NULL
T32-DKO07186	NULL
(	NULL
to	NULL
S.B.K	NULL
.	NULL
)	NULL

and	NULL
HL	NULL
57393	NULL
and	NULL
P30ESO00267	NULL
(	NULL
to	NULL
ZZ	NULL
.	NULL
)	NULL

from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
and	NULL
Markey	NULL
Trust	NULL
Funds	NULL
(	NULL
to	NULL
ZZ	NULL
.	NULL
)	NULL

.	NULL

XS	NULL
.	NULL

is	NULL
an	NULL
Ortho	NULL
Biotech	NULL
Hematology	NULL
Fellow	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Sanford	NULL
B.	NULL
Krantz	NULL
,	NULL
MD	NULL
,	NULL
or	NULL
Zhizhuang	NULL
Zhao	NULL
,	NULL
PhD	NULL
,	NULL
Department	NULL
of	NULL
Medicine/Hematology	NULL
,	NULL
Vanderbilt	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
MRBII	NULL
,	NULL
Nashville	NULL
,	NULL
TN	NULL
37232-6305	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/98/9204-0039	NULL
$	NULL
3.00/0	NULL
1142	NULL
duced	NULL
by	NULL
EPO	NULL
but	NULL
not	NULL
that	NULL
by	NULL
SCF	NULL
,	NULL
suggesting	NULL
that	NULL
SCF	NULL
and	NULL
EPO	NULL
may	NULL
activate	NULL
MAPK	NULL
through	NULL
different	NULL
pathways	NULL
,	NULL
which	NULL
would	NULL
facilitate	NULL
synergy	NULL
.	NULL

Furthermore	NULL
,	NULL
EPO	NULL
,	NULL
but	NULL
not	NULL
SCF	NULL
,	NULL
led	NULL
to	NULL
activation	NULL
of	NULL
STAT5	NULL
,	NULL
whereas	NULL
SCF	NULL
and	NULL
wortmannin	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
EPO-induced	NULL
STATS	NULL
activation	NULL
,	NULL
suggesting	NULL
that	NULL
STATS	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
synergistic	NULL
action	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
.	NULL

Together	NULL
,	NULL
the	NULL
data	NULL
suggest	NULL
that	NULL
synergistic	NULL
activation	NULL
of	NULL
M	NULL
APK	NULL
by	NULL
SCF	NULL
and	NULL
EPO	NULL
is	NULL
essential	NULL
for	NULL
expanded	NULL
erythropoiesis	NULL
.	NULL

©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

performed	NULL
a	NULL
study	NULL
using	NULL
primary	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
,	NULL
although	NULL
SCF	NULL
can	NULL
induce	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
,	NULL
it	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
transduce	NULL
signals	NULL
via	NULL
EPO-R	NULL
and	NULL
support	NULL
cell	NULL
growth	NULL
.	NULL

Instead	NULL
,	NULL
our	NULL
data	NULL
show	NULL
that	NULL
SCF	NULL
and	NULL
EPO	NULL
synergistically	NULL
activate	NULL
MAP	NULL
kinase	NULL
(	NULL
MAPK	NULL
,	NULL
ERK1/2	NULL
)	NULL
,	NULL
which	NULL
correlates	NULL
with	NULL
the	NULL
cell	NULL
growth	NULL
and	NULL
thus	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
synergistic	NULL
effects	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
.	NULL

-	NULL
Recombinant	NULL
human	NULL
(	NULL
rh	NULL
)	NULL
SCF	NULL
and	NULL
rhEPO	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Amgen	NULL
,	NULL
Inc	NULL
(	NULL
Thousand	NULL
Oaks	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
Ortho	NULL
Biotech	NULL
,	NULL
Inc	NULL
(	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Rabbit	NULL
phospho-specific	NULL
MAPK	NULL
and	NULL
MEK	NULL
1/2	NULL
(	NULL
Ser217/221	NULL
)	NULL
antibodies	NULL
were	NULL
purchased	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc	NULL
(	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Phospho-specific	NULL
MAPK	NULL
antibody	NULL
detects	NULL
p42	NULL
and	NULL
p44	NULL
(	NULL
Erk1	NULL
and	NULL
Erk2	NULL
)	NULL
only	NULL
when	NULL
catalytically	NULL
activated	NULL
by	NULL
phosphorylation	NULL
at	NULL
Tyr	NULL
204	NULL
.	NULL

Rabbit	NULL
anti-MAPK	NULL
polyclonal	NULL
antibody	NULL
(	NULL
7884	NULL
)	NULL
was	NULL
raised	NULL
in	NULL
rabbits	NULL
against	NULL
a	NULL
22-amino	NULL
acid	NULL
peptide	NULL
derived	NULL
from	NULL
the	NULL
subdomain	NULL
X1	NULL
of	NULL
MAPK	NULL
and	NULL
recognized	NULL
both	NULL
Erk1	NULL
and	NULL
Erk2	NULL
.	NULL

``	NULL
2	NULL
Rabbit	NULL
polyclonal	NULL
EPO	NULL
receptor	NULL
(	NULL
EPOR	NULL
)	NULL
,	NULL
c-Kit	NULL
,	NULL
and	NULL
STAT	NULL
5b	NULL
(	NULL
C-17	NULL
;	NULL
catalogue	NULL
no	NULL
.	NULL

sc-835	NULL
;	NULL
recognizes	NULL
both	NULL
STAT	NULL
5a	NULL
and	NULL
5b	NULL
)	NULL
antibodies	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Mouse	NULL
antiphospho-tyrosine	NULL
antibody	NULL
4G-10	NULL
was	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Inc	NULL
(	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

MEK1	NULL
inhibitor	NULL
(	NULL
PD98059	NULL
)	NULL
was	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc	NULL
,	NULL
and	NULL
phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
PI3-kinase	NULL
)	NULL
inhibitor	NULL
Wortmannin	NULL
from	NULL
Calbiochem	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

[	NULL
y-	NULL
>	NULL
2P	NULL
]	NULL
-dCTP	NULL
and	NULL
[	NULL
y-	NULL
>	NULL
2P	NULL
]	NULL
-dTTP	NULL
,	NULL
[	NULL
y-	NULL
>	NULL
2P	NULL
]	NULL
-ATP	NULL
,	NULL
and	NULL
horseradish	NULL
peroxidase-conjugated	NULL
secondary	NULL
antibodies	NULL
were	NULL
from	NULL
Amersham	NULL
Corp	NULL
(	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Two	NULL
buffers	NULL
were	NULL
used	NULL
for	NULL
extraction	NULL
of	NULL
proteins	NULL
from	NULL
ECFC	NULL
.	NULL

Buffer	NULL
A	NULL
consisted	NULL
of	NULL
50	NULL
mmol/L	NULL
B-glycerophosphate	NULL
(	NULL
pH	NULL
7.3	NULL
)	NULL
,	NULL
2	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
1	NULL
mmol/L	NULL
EGTA	NULL
,	NULL
5	NULL
mmol/L	NULL
B-mercaptoethanol	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
and	NULL
0.1	NULL
mol/L	NULL
NaCl	NULL
.	NULL

Buffer	NULL
B	NULL
consisted	NULL
of	NULL
20	NULL
mmol/L	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
20	NULL
mmol/L	NULL
NaF	NULL
,	NULL
1	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
and	NULL
1	NULL
mmol/L	NULL
dithiothreitol	NULL
.	NULL

Both	NULL
buffers	NULL
were	NULL
also	NULL
supplemented	NULL
with	NULL
0.2	NULL
mmol/L	NULL
NasVO4	NULL
,	NULL
0.1	NULL
umol/L	NULL
microcystin	NULL
,	NULL
1.0	NULL
mmol/L	NULL
benzamidine	NULL
,	NULL
0.1	NULL
mmol/L	NULL
phenylmethysulfo-nyl	NULL
fluoride	NULL
,	NULL
2	NULL
ug/mL	NULL
leupeptin	NULL
,	NULL
1	NULL
pmol/L	NULL
pepstain	NULL
A	NULL
,	NULL
and	NULL
1	NULL
pg/mL	NULL
aprotinin	NULL
.	NULL

Preparation	NULL
of	NULL
erythroid	NULL
colony-forming	NULL
cells	NULL
(	NULL
ECFC	NULL
)	NULL
.	NULL

-	NULL
Purification	NULL
of	NULL
human	NULL
ECFC	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
reported	NULL
,	NULL
with	NULL
minor	NULL
modification	NULL
.	NULL
``	NULL

Four	NULL
hundred	NULL
milliliters	NULL
of	NULL
heparinized	NULL
peripheral	NULL
blood	NULL
was	NULL
obtained	NULL
from	NULL
healthy	NULL
donor	NULL
,	NULL
after	NULL
informed	NULL
consent	NULL
was	NULL
obtained	NULL
,	NULL
which	NULL
was	NULL
approved	NULL
by	NULL
the	NULL
Vanderbilt	NULL
Committee	NULL
for	NULL
the	NULL
Protection	NULL
of	NULL
Human	NULL
Subjects	NULL
.	NULL

The	NULL
light-density	NULL
mononuclear	NULL
cells	NULL
were	NULL
separated	NULL
on	NULL
Ficoll-Hypaque	NULL
(	NULL
F-H	NULL
;	NULL
1.077	NULL
g/mL	NULL
)	NULL
at	NULL
400g	NULL
at	NULL
24°C	NULL
for	NULL
25	NULL
minutes	NULL
by	NULL
centrifugation	NULL
.	NULL

The	NULL
interface	NULL
mononuclear	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
Dulbecco	NULL
's	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
D-PBS	NULL
)	NULL
,	NULL
and	NULL
then	NULL
overlaid	NULL
on	NULL
30	NULL
mL	NULL
of	NULL
10	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
in	NULL
D-PBS	NULL
at	NULL
180g	NULL
at	NULL
24°C	NULL
for	NULL
10	NULL
Blood	NULL
,	NULL
Vol	NULL
92	NULL
,	NULL
No	NULL
4	NULL
(	NULL
August	NULL
15	NULL
)	NULL
,	NULL
1998	NULL
:	NULL
pp	NULL
1142-1149	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

SYNERGISTIC	NULL
ACTIVATION	NULL
OF	NULL
MAPK	NULL
BY	NULL
EPO	NULL
AND	NULL
SCF	NULL
minutes	NULL
to	NULL
remove	NULL
platelets	NULL
.	NULL

This	NULL
step	NULL
was	NULL
repeated	NULL
once	NULL
and	NULL
then	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
one-half	NULL
volume	NULL
of	NULL
neuraminidase-treated	NULL
and	NULL
one-half	NULL
volume	NULL
of	NULL
IgG-coated	NULL
sheep	NULL
red	NULL
blood	NULL
cells	NULL
(	NULL
RBCs	NULL
)	NULL
.	NULL

After	NULL
centrifugation	NULL
at	NULL
130g	NULL
at	NULL
24°C	NULL
for	NULL
10	NULL
minutes	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
placed	NULL
in	NULL
ice	NULL
for	NULL
60	NULL
minutes	NULL
and	NULL
then	NULL
separated	NULL
over	NULL
F-H	NULL
at	NULL
400g	NULL
at	NULL
24°C	NULL
for	NULL
10	NULL
minutes	NULL
to	NULL
remove	NULL
the	NULL
rosetted	NULL
lymphocytes	NULL
.	NULL

The	NULL
interface	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
overnight	NULL
at	NULL
37°C	NULL
in	NULL
Iscove	NULL
's	NULL
modified	NULL
Dulbecco	NULL
's	NULL
medium	NULL
(	NULL
IMDM	NULL
)	NULL
containing	NULL
20	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
,	NULL
1	NULL
%	NULL
BSA	NULL
,	NULL
and	NULL
4	NULL
%	NULL
giant	NULL
cell	NULL
tumor	NULL
(	NULL
GCT	NULL
)	NULL
-conditioned	NULL
medium	NULL
to	NULL
remove	NULL
adherent	NULL
cells	NULL
.	NULL

The	NULL
nonadherent	NULL
cells	NULL
were	NULL
collected	NULL
the	NULL
next	NULL
day	NULL
(	NULL
day	NULL
1	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
mouse	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
CD11b	NULL
,	NULL
CD2	NULL
,	NULL
CD4SR	NULL
,	NULL
and	NULL
CD16	NULL
for	NULL
60	NULL
minutes	NULL
at	NULL
4°C	NULL
on	NULL
a	NULL
gently	NULL
rocking	NULL
platform	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
IMDM	NULL
containing	NULL
2	NULL
%	NULL
FCS	NULL
and	NULL
resuspended	NULL
in	NULL
IMDM	NULL
containing	NULL
5	NULL
%	NULL
FCS	NULL
.	NULL

Five-milliliter	NULL
aliquots	NULL
were	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
90	NULL
minutes	NULL
in	NULL
100-mm	NULL
plastic	NULL
tissue	NULL
culture	NULL
dishes	NULL
(	NULL
100	NULL
X	NULL
200	NULL
)	NULL
coated	NULL
with	NULL
affinity-purified	NULL
goat	NULL
antimurine	NULL
IgG	NULL
to	NULL
remove	NULL
the	NULL
antibody-positive	NULL
cells	NULL
.	NULL
``	NULL

The	NULL
antibody-negative	NULL
nonadherent	NULL
cells	NULL
were	NULL
then	NULL
collected	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
are	NULL
refered	NULL
to	NULL
as	NULL
day-1	NULL
cells	NULL
.	NULL

The	NULL
collected	NULL
day-1	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
a	NULL
suspension	NULL
mixture	NULL
containing	NULL
30	NULL
%	NULL
FCS	NULL
,	NULL
1	NULL
%	NULL
deionized	NULL
BSA	NULL
,	NULL
2	NULL
U/mL	NULL
of	NULL
thEPO	NULL
,	NULL
100	NULL
ng/mL	NULL
of	NULL
thSCF	NULL
,	NULL
50	NULL
U/mL	NULL
of	NULL
rhIL-3	NULL
,	NULL
10	NULL
ug/ml	NULL
of	NULL
insulin	NULL
,	NULL
10~*	NULL
mol/L	NULL
of	NULL
2-mercaptoethanol	NULL
,	NULL
500	NULL
U/mL	NULL
of	NULL
penicillin	NULL
,	NULL
and	NULL
40	NULL
ug/ml	NULL
of	NULL
streptomycin	NULL
in	NULL
IMDM	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
high	NULL
humidity	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
,	NULL
95	NULL
%	NULL
air	NULL
incubator	NULL
.	NULL

At	NULL
day	NULL
6	NULL
of	NULL
the	NULL
suspension	NULL
culture	NULL
,	NULL
equal	NULL
volumes	NULL
of	NULL
fresh	NULL
IMDM	NULL
containing	NULL
20	NULL
%	NULL
FCS	NULL
and	NULL
1	NULL
%	NULL
BSA	NULL
and	NULL
additional	NULL
doses	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
were	NULL
added	NULL
to	NULL
the	NULL
culture	NULL
.	NULL

The	NULL
cultured	NULL
cells	NULL
were	NULL
collected	NULL
at	NULL
day	NULL
8	NULL
of	NULL
suspension	NULL
culture	NULL
,	NULL
and	NULL
these	NULL
cells	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
day-8	NULL
ECFC	NULL
.	NULL

Compared	NULL
with	NULL
the	NULL
day-6	NULL
ECFC	NULL
used	NULL
in	NULL
our	NULL
previous	NULL
study	NULL
,	NULL
``	NULL
``	NULL
the	NULL
yield	NULL
and	NULL
purity	NULL
of	NULL
day-8	NULL
ECFC	NULL
were	NULL
significantly	NULL
increased	NULL
with	NULL
this	NULL
modified	NULL
method	NULL
(	NULL
yield	NULL
:	NULL
3	NULL
to	NULL
5	NULL
times	NULL
more	NULL
than	NULL
that	NULL
at	NULL
day	NULL
6	NULL
;	NULL
purity	NULL
:	NULL
80	NULL
%	NULL
+	NULL
4.6	NULL
%	NULL
v	NULL
63	NULL
%	NULL
+	NULL
7.9	NULL
%	NULL
)	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
the	NULL
ECFC	NULL
refers	NULL
to	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
that	NULL
can	NULL
form	NULL
erythroid	NULL
colonies	NULL
in	NULL
the	NULL
plasma	NULL
assay	NULL
.	NULL
``	NULL

The	NULL
cells	NULL
that	NULL
can	NULL
not	NULL
form	NULL
colonies	NULL
are	NULL
mainly	NULL
proerythroblasts	NULL
and	NULL
erythroblasts	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
cytospin	NULL
mophological	NULL
studies	NULL
.	NULL

The	NULL
day-8	NULL
ECFC	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
and	NULL
used	NULL
for	NULL
all	NULL
further	NULL
studies	NULL
.	NULL

Cell	NULL
starvation	NULL
and	NULL
stimulation	NULL
.	NULL

-	NULL
After	NULL
washing	NULL
with	NULL
PBS	NULL
,	NULL
day-8	NULL
ECFC	NULL
were	NULL
resuspended	NULL
at	NULL
a	NULL
cell	NULL
density	NULL
of	NULL
2	NULL
to	NULL
5	NULL
X	NULL
105/mL	NULL
in	NULL
IMDM	NULL
containing	NULL
0.1	NULL
%	NULL
BSA	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
once	NULL
again	NULL
with	NULL
PBS	NULL
and	NULL
reincubated	NULL
at	NULL
37°C	NULL
for	NULL
an	NULL
additional	NULL
2	NULL
hours	NULL
.	NULL

After	NULL
the	NULL
serum-deprived	NULL
starvation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
EPO	NULL
and	NULL
SCF	NULL
at	NULL
their	NULL
optimal	NULL
concentrations	NULL
for	NULL
various	NULL
periods	NULL
of	NULL
time	NULL
.	NULL

Optimal	NULL
concentrations	NULL
of	NULL
SCF	NULL
at	NULL
100	NULL
ng/mL	NULL
and	NULL
EPO	NULL
at	NULL
40	NULL
U/mL	NULL
were	NULL
obtained	NULL
from	NULL
dose-response	NULL
experiments	NULL
.	NULL

Activation	NULL
of	NULL
MAPK	NULL
induced	NULL
by	NULL
SCF	NULL
and	NULL
EPO	NULL
in	NULL
human	NULL
ECFC	NULL
reached	NULL
plateaus	NULL
at	NULL
these	NULL
concentrations	NULL
,	NULL
respectively	NULL
.	NULL

These	NULL
are	NULL
concentrations	NULL
at	NULL
which	NULL
the	NULL
receptors	NULL
(	NULL
EPO	NULL
,	NULL
c-Kit	NULL
)	NULL
on	NULL
the	NULL
ECFC	NULL
cell	NULL
surface	NULL
are	NULL
completely	NULL
saturated	NULL
.	NULL
'	NULL

>	NULL
``	NULL
``	NULL
For	NULL
studies	NULL
involving	NULL
kinase	NULL
inhibitors	NULL
(	NULL
PD98059	NULL
and	NULL
Wortmanin	NULL
}	NULL
,	NULL
the	NULL
ECFC	NULL
were	NULL
preincubated	NULL
with	NULL
the	NULL
inhibitors	NULL
at	NULL
varying	NULL
concentrations	NULL
for	NULL
1	NULL
hour	NULL
before	NULL
stimulation	NULL
or	NULL
further	NULL
cell	NULL
culture	NULL
.	NULL

The	NULL
stimulation	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
10	NULL
vol	NULL
of	NULL
cold	NULL
PBS	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
lysed	NULL
in	NULL
buffer	NULL
A	NULL
for	NULL
whole	NULL
cell	NULL
extraction	NULL
.	NULL

For	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
,	NULL
the	NULL
pelleted	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
three	NULL
packed	NULL
cell	NULL
volume	NULL
of	NULL
hypotonic	NULL
buffer	NULL
B	NULL
,	NULL
swollen	NULL
for	NULL
10	NULL
minutes	NULL
,	NULL
and	NULL
lysed	NULL
by	NULL
repeated	NULL
passage	NULL
through	NULL
a	NULL
25-gauge	NULL
needle	NULL
.	NULL

Nuclei	NULL
were	NULL
collected	NULL
and	NULL
washed	NULL
by	NULL
centrifugation	NULL
at	NULL
16,0005	NULL
for	NULL
10	NULL
minutes	NULL
and	NULL
then	NULL
extracted	NULL
in	NULL
buffer	NULL
A	NULL
supplemented	NULL
with	NULL
0.42	NULL
mol/L	NULL
NaCl	NULL
and	NULL
20	NULL
%	NULL
glycerol	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

The	NULL
supernatants	NULL
(	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
nuclear	NULL
extracts	NULL
)	NULL
were	NULL
cleared	NULL
by	NULL
centrifugation	NULL
at	NULL
16,0005	NULL
for	NULL
1	NULL
minute	NULL
and	NULL
used	NULL
for	NULL
STAT	NULL
activity	NULL
analyses	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
assays	NULL
of	NULL
STATs	NULL
.	NULL

The	NULL
activities	NULL
of	NULL
STATs	NULL
were	NULL
determined	NULL
by	NULL
analyzing	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
protein	NULL
to	NULL
form	NULL
complexes	NULL
with	NULL
specific	NULL
DNA	NULL
probes	NULL
in	NULL
gel	NULL
shift	NULL
assays	NULL
.	NULL

The	NULL
DNA	NULL
probes	NULL
used	NULL
were	NULL
PIE-derived	NULL
from	NULL
a	NULL
prolactin-inducible	NULL
element	NULL
and	NULL
hSIE	NULL
,	NULL
a	NULL
high-affinity	NULL
sequence	NULL
for	NULL
the	NULL
sis-inducible	NULL
element	NULL
of	NULL
the	NULL
fos	NULL
promotor	NULL
.	NULL

PIE	NULL
is	NULL
specifically	NULL
for	NULL
detection	NULL
of	NULL
STATS	NULL
,	NULL
whereas	NULL
hSIE	NULL
contains	NULL
1143	NULL
high	NULL
affinity	NULL
binding	NULL
sites	NULL
for	NULL
STAT1	NULL
and	NULL
STAT3	NULL
.	NULL

PIE	NULL
and	NULL
SIE	NULL
were	NULL
made	NULL
by	NULL
annealing	NULL
5'-AGATTTCTAGGAATTCAA-3	NULL
'	NULL
with	NULL
5'-GGATTGAATTCCTAGAAA-3	NULL
'	NULL
and	NULL
5-GTCGACATTTCCCGTAAATC-3	NULL
'	NULL
with	NULL
5'-TCGACGATTTACGGGAAATG3	NULL
'	NULL
,	NULL
respectively	NULL
.	NULL

'*	NULL
These	NULL
double-stranded	NULL
DNA	NULL
probes	NULL
with	NULL
staggered	NULL
ends	NULL
were	NULL
labeled	NULL
by	NULL
Klenow	NULL
fragment	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
y-	NULL
>	NULL
P	NULL
]	NULL
dCTP	NULL
and	NULL
[	NULL
y-	NULL
>	NULL
P	NULL
]	NULL
dTTP	NULL
for	NULL
PIE	NULL
and	NULL
[	NULL
y-	NULL
>	NULL
2P	NULL
]	NULL
dCTP	NULL
alone	NULL
for	NULL
SIE	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

Free	NULL
nucleotides	NULL
were	NULL
removed	NULL
by	NULL
using	NULL
a	NULL
nucleotide	NULL
removing	NULL
kit	NULL
from	NULL
Qiagen	NULL
(	NULL
Chatsworth	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
containing	NULL
10	NULL
ug	NULL
protein	NULL
were	NULL
preincubated	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
for	NULL
10	NULL
minutes	NULL
,	NULL
which	NULL
was	NULL
followed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
2	NULL
mL	NULL
3°P-labeled	NULL
DNA	NULL
probes	NULL
and	NULL
further	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
an	NULL
additional	NULL
15	NULL
minutes	NULL
.	NULL

The	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
resolved	NULL
on	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
(	NULL
acrylamide	NULL
:	NULL
bisacrylamide	NULL
=	NULL
39:1	NULL
)	NULL
containing	NULL
2.5	NULL
%	NULL
glycerol	NULL
made	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
buffer	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
on	NULL
x-ray	NULL
film	NULL
.	NULL

MAPK	NULL
activity	NULL
assay	NULL
.	NULL

The	NULL
whole	NULL
cell	NULL
extracts	NULL
made	NULL
in	NULL
buffer	NULL
A	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
phospho-specific	NULL
MAPK	NULL
antibody	NULL
,	NULL
and	NULL
the	NULL
MAPK	NULL
activity	NULL
in	NULL
the	NULL
immunoprecipitates	NULL
was	NULL
assayed	NULL
with	NULL
myelin	NULL
basic	NULL
protein	NULL
(	NULL
MBP	NULL
)	NULL
as	NULL
a	NULL
substrate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
y-	NULL
>	NULL
°P	NULL
]	NULL
-ATP	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

Suspension	NULL
and	NULL
colony	NULL
assays	NULL
.	NULL

-	NULL
Suspension	NULL
and	NULL
plasma-clot	NULL
assays	NULL
of	NULL
ECFC	NULL
were	NULL
performed	NULL
as	NULL
we	NULL
previously	NULL
reported	NULL
.	NULL
'	NULL

>	NULL
``	NULL
``	NULL
Cell	NULL
numbers	NULL
in	NULL
the	NULL
serum-containing	NULL
suspension	NULL
culture	NULL
were	NULL
determined	NULL
every	NULL
other	NULL
day	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
kinase	NULL
inhibitor	NULL
on	NULL
cell	NULL
growth	NULL
,	NULL
the	NULL
ECFC	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
varying	NULL
concentration	NULL
of	NULL
inhibitors	NULL
.	NULL

Because	NULL
both	NULL
PD98059	NULL
and	NULL
Wortmannin	NULL
were	NULL
reconstituted	NULL
in	NULL
dimethyl	NULL
sulfoxide	NULL
(	NULL
DMSO	NULL
)	NULL
and	NULL
DMSO	NULL
might	NULL
have	NULL
toxic	NULL
effects	NULL
on	NULL
the	NULL
cells	NULL
,	NULL
the	NULL
final	NULL
concentration	NULL
of	NULL
DMSO	NULL
in	NULL
all	NULL
culture	NULL
was	NULL
limited	NULL
to	NULL
less	NULL
than	NULL
0.2	NULL
%	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
no	NULL
effects	NULL
on	NULL
ECFC	NULL
growth	NULL
in	NULL
our	NULL
studies	NULL
.	NULL

Plasma	NULL
clot	NULL
culture	NULL
was	NULL
maintained	NULL
for	NULL
7	NULL
days	NULL
and	NULL
the	NULL
colonies	NULL
formed	NULL
were	NULL
fixed	NULL
and	NULL
stained	NULL
with	NULL
3,3	NULL
'	NULL
dimethoxybenzidine	NULL
and	NULL
hematoxylin	NULL
for	NULL
enumeration	NULL
of	NULL
erythroid	NULL
colonies	NULL
.	NULL

Sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-gels	NULL
and	NULL
Western	NULL
blotting	NULL
.	NULL

Protein	NULL
extracts	NULL
were	NULL
separated	NULL
by	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophore-sis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
polyvinylidene	NULL
difluoride	NULL
(	NULL
PVDF	NULL
)	NULL
membranes	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
probed	NULL
with	NULL
various	NULL
primary	NULL
antibodies	NULL
that	NULL
were	NULL
detected	NULL
by	NULL
using	NULL
the	NULL
enhanced	NULL
chemilumi-nescence	NULL
(	NULL
ECL	NULL
)	NULL
system	NULL
with	NULL
horseradish	NULL
peroxidase-conjugated	NULL
secondary	NULL
antibodies	NULL
(	NULL
Amersham	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
.	NULL

RESULTS	NULL
SCF	NULL
induces	NULL
transient	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
,	NULL
but	NULL
can	NULL
not	NULL
replace	NULL
EPO	NULL
to	NULL
support	NULL
erythropoiesis	NULL
in	NULL
vitro	NULL
.	NULL

-	NULL
Over	NULL
the	NULL
past	NULL
years	NULL
,	NULL
we	NULL
have	NULL
established	NULL
a	NULL
method	NULL
to	NULL
purify	NULL
large	NULL
amounts	NULL
of	NULL
human	NULL
ECFC	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
.	NULL
``	NULL

''	NULL
Our	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
these	NULL
cells	NULL
at	NULL
day	NULL
6	NULL
to	NULL
8	NULL
express	NULL
about	NULL
1,000	NULL
EPO-R	NULL
and	NULL
23,000	NULL
c-Kit	NULL
receptors	NULL
per	NULL
cell	NULL
and	NULL
are	NULL
highly	NULL
sensitive	NULL
to	NULL
treatment	NULL
with	NULL
SCF	NULL
and	NULL
EPO	NULL
.	NULL

A	NULL
majority	NULL
of	NULL
these	NULL
cells	NULL
are	NULL
able	NULL
to	NULL
form	NULL
RBC	NULL
colonies	NULL
in	NULL
semisolid	NULL
cultures	NULL
.	NULL

!	NULL

36	NULL
!	NULL
``	NULL

These	NULL
highly	NULL
purified	NULL
ECFC	NULL
thus	NULL
provide	NULL
a	NULL
good	NULL
primary	NULL
cell	NULL
system	NULL
to	NULL
study	NULL
cell	NULL
signaling	NULL
.	NULL

To	NULL
explore	NULL
the	NULL
mechanisms	NULL
for	NULL
the	NULL
synergism	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
,	NULL
we	NULL
first	NULL
examined	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
and	NULL
c-Kit	NULL
after	NULL
stimulation	NULL
by	NULL
their	NULL
ligands	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
1A	NULL
and	NULL
B	NULL
,	NULL
both	NULL
SCF	NULL
and	NULL
EPO	NULL
stimulated	NULL
rapid	NULL
and	NULL
transient	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
their	NULL
own	NULL
receptors	NULL
,	NULL
respectively	NULL
.	NULL

Stimulation	NULL
of	NULL
cells	NULL
with	NULL
SCF	NULL
alone	NULL
also	NULL
induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
,	NULL
although	NULL
the	NULL
degree	NULL
of	NULL
phosphorylation	NULL
was	NULL
less	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
EPO	NULL
and	NULL
disappeared	NULL
after	NULL
10	NULL
minutes	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EPO	NULL
,	NULL
SCF	NULL
appeared	NULL
to	NULL
show	NULL
no	NULL
enhancing	NULL
effect	NULL
on	NULL
EPO-R	NULL
phosphorylation	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

Whereas	NULL
SCF	NULL
alone	NULL
possessed	NULL
some	NULL
effect	NULL
on	NULL
EPOR	NULL
phosphorylation	NULL
,	NULL
EPO	NULL
alone	NULL
had	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1144	NULL
A	NULL
1°	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
IP	NULL
:	NULL
anti-c-Kit	NULL
ua	NULL
Blot	NULL
:	NULL
Anti-PY	NULL
-	NULL
--	NULL
-	NULL
@	NULL
@	NULL
@	NULL
@	NULL
--	NULL
<	NULL
@	NULL
@	NULL
a	NULL
e	NULL
aw	NULL
-	NULL
-ss0	NULL
)	NULL
.	NULL
'	NULL

.	NULL
'	NULL

”	NULL
.ﬂ	NULL
-a-	NULL
c-Kit	NULL
Reblot	NULL
:	NULL
Anti-c-Kit	NULL
#	NULL
0	NULL
0	NULL
#	NULL
®	NULL
WW	NULL
-sco	NULL
Stimulation	NULL
(	NULL
min	NULL
)	NULL
_	NULL
Q	NULL
510	NULL
51410	NULL
5o	NULL
10	NULL
0	NULL
£	NULL
£	NULL
4	NULL
$	NULL
&	NULL
&	NULL
5	NULL
B	NULL
10	NULL
2	NULL
B3	NULL
40	NULL
50	NULL
60	NULL
7	NULL
IP	NULL
:	NULL
anti-EPOR	NULL
wae	NULL
thi	NULL
wha	NULL
ams	NULL
waue	NULL
|	NULL
4-EPOR	NULL
Blot	NULL
:	NULL
anti-PY	NULL
“	NULL
d	NULL
...	NULL
..	NULL
-	NULL
«	NULL
4-1gG	NULL
(	NULL
H	NULL
)	NULL
Reblot	NULL
:	NULL
anti-EPOR	NULL
-a-EPOR	NULL
@	NULL
pear	NULL
<	NULL
-IgG	NULL
(	NULL
H	NULL
)	NULL
Stimulation	NULL
(	NULL
min	NULL
)	NULL
y	NULL
&	NULL
&	NULL
&	NULL
no	NULL
effect	NULL
on	NULL
c-Kit	NULL
phosphorylation	NULL
,	NULL
and	NULL
a	NULL
combination	NULL
of	NULL
SCF	NULL
with	NULL
EPO	NULL
did	NULL
not	NULL
enhance	NULL
SCF-induced	NULL
c-Kit	NULL
phosphorylation	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
EPO-R	NULL
upon	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
SCF	NULL
confirms	NULL
the	NULL
results	NULL
reported	NULL
by	NULL
others	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
no	NULL
physical	NULL
association	NULL
between	NULL
these	NULL
two	NULL
receptors	NULL
was	NULL
observed	NULL
,	NULL
because	NULL
Western	NULL
blotting	NULL
of	NULL
EPO-R	NULL
immunoprecipitates	NULL
with	NULL
c-Kit	NULL
antibody	NULL
or	NULL
c-Kit	NULL
immunoprecipitates	NULL
with	NULL
EPO-R	NULL
antibody	NULL
did	NULL
not	NULL
show	NULL
any	NULL
coimmunoprecipitation	NULL
of	NULL
one	NULL
receptor	NULL
with	NULL
the	NULL
other	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
next	NULL
determined	NULL
whether	NULL
SCF	NULL
could	NULL
stimulate	NULL
erythroid	NULL
cell	NULL
growth	NULL
while	NULL
inducing	NULL
EPO-R	NULL
phosphorylation	NULL
.	NULL

Figure	NULL
1C	NULL
shows	NULL
the	NULL
growth	NULL
of	NULL
erythroid	NULL
cells	NULL
in	NULL
suspension	NULL
culture	NULL
.	NULL

Compared	NULL
with	NULL
the	NULL
synergistically	NULL
stimulated	NULL
cell	NULL
growth	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
EPO	NULL
and	NULL
SCF	NULL
,	NULL
EPO	NULL
alone	NULL
manifested	NULL
only	NULL
20	NULL
%	NULL
to	NULL
25	NULL
%	NULL
of	NULL
this	NULL
erythroid	NULL
cell	NULL
production	NULL
from	NULL
ECFC	NULL
over	NULL
a	NULL
period	NULL
of	NULL
7	NULL
days	NULL
,	NULL
whereas	NULL
SCF	NULL
alone	NULL
did	NULL
not	NULL
support	NULL
cell	NULL
growth	NULL
at	NULL
all	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
the	NULL
erythroid	NULL
colony-forming	NULL
assays	NULL
with	NULL
semisolid	NULL
culture	NULL
medium	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
SCF	NULL
to	NULL
EPO	NULL
significantly	NULL
increased	NULL
both	NULL
the	NULL
number	NULL
and	NULL
the	NULL
size	NULL
of	NULL
RBC	NULL
colonies	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
,	NULL
although	NULL
SCF	NULL
can	NULL
induce	NULL
transient	NULL
phosphor	NULL
SUI	NULL
ET	NULL
AL	NULL
C	NULL
15	NULL
p	NULL
--	NULL
LD	NULL
--	NULL
_	NULL
Control	NULL
hees	NULL
--	NULL
A-	NULL
_	NULL
SCF	NULL
J	NULL
107	NULL
-o-	NULL
_	NULL
EPO	NULL
5	NULL
-O-	NULL
_	NULL
SCF.EPO	NULL
a	NULL
€	NULL
3	NULL
2	NULL
pr	NULL
O	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
Days	NULL
in	NULL
Culture	NULL
Fig	NULL
1	NULL
.	NULL

SCF	NULL
causes	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
,	NULL
but	NULL
can	NULL
not	NULL
replace	NULL
EPO	NULL
to	NULL
support	NULL
human	NULL
erythropoiesis	NULL
in	NULL
vitro	NULL
.	NULL

Phosphorylation	NULL
of	NULL
c-Kit	NULL
(	NULL
A	NULL
)	NULL
and	NULL
EPO-R	NULL
(	NULL
B	NULL
)	NULL
after	NULL
stimulation	NULL
of	NULL
ECFC	NULL
with	NULL
EPO	NULL
,	NULL
SCF	NULL
,	NULL
or	NULL
EPO	NULL
+	NULL
SCF	NULL
.	NULL

Replicate	NULL
day-8	NULL
ECFC	NULL
(	NULL
~5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
starved	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
SCF	NULL
and	NULL
EPO	NULL
separately	NULL
or	NULL
in	NULL
combination	NULL
for	NULL
5	NULL
or	NULL
10	NULL
minutes	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
subject	NULL
to	NULL
immunoprecipitation	NULL
with	NULL
anti-c-Kit	NULL
and	NULL
anti-EPO-R	NULL
antibodies	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
beads	NULL
.	NULL

Immunoprecipitates	NULL
(	NULL
corresponding	NULL
to	NULL
whole	NULL
cell	NULL
extracts	NULL
containing	NULL
50	NULL
pg	NULL
of	NULL
total	NULL
protein	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
with	NULL
antiphos-photyrosine	NULL
antibody	NULL
4G-10	NULL
.	NULL

(	NULL
C	NULL
)	NULL
To	NULL
determine	NULL
the	NULL
requirement	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
for	NULL
growth	NULL
of	NULL
ECFC	NULL
,	NULL
day-6	NULL
ECFC	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
20	NULL
%	NULL
FBS	NULL
,	NULL
1	NULL
%	NULL
BSA-containing	NULL
medium	NULL
supplemented	NULL
with	NULL
SCF	NULL
,	NULL
EPO	NULL
,	NULL
or	NULL
SCF	NULL
+	NULL
EPO	NULL
.	NULL

Cell	NULL
numbers	NULL
were	NULL
determined	NULL
after	NULL
7	NULL
days	NULL
in	NULL
culture	NULL
.	NULL

Data	NULL
represent	NULL
the	NULL
mean	NULL
values	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

ylation	NULL
of	NULL
EPO-R	NULL
on	NULL
tyrosine	NULL
,	NULL
it	NULL
can	NULL
not	NULL
replace	NULL
EPO	NULL
to	NULL
support	NULL
erythroid	NULL
cell	NULL
growth	NULL
.	NULL

Thus	NULL
,	NULL
SCF-induced	NULL
EPO-R	NULL
phosphorylation	NULL
may	NULL
not	NULL
be	NULL
sufficient	NULL
to	NULL
activate	NULL
EPO-R	NULL
and	NULL
transduce	NULL
signals	NULL
through	NULL
it	NULL
.	NULL

The	NULL
synergistic	NULL
effects	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
on	NULL
erythropoiesis	NULL
are	NULL
most	NULL
likely	NULL
mediated	NULL
by	NULL
intracellular	NULL
signaling	NULL
events	NULL
downstream	NULL
of	NULL
the	NULL
receptors	NULL
.	NULL

SCF	NULL
and	NULL
EPO	NULL
synergistically	NULL
activate	NULL
MAPK	NULL
in	NULL
human	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

-	NULL
MAP	NULL
kinase	NULL
(	NULL
MAPK	NULL
,	NULL
ERK1/2	NULL
)	NULL
is	NULL
a	NULL
major	NULL
transducer	NULL
of	NULL
extracellular	NULL
mitogenic	NULL
signals	NULL
that	NULL
promote	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
,	NULL
``	NULL
?	NULL

and	NULL
we	NULL
thought	NULL
that	NULL
it	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
synergistic	NULL
effects	NULL
of	NULL
EPO	NULL
and	NULL
SCF	NULL
on	NULL
erythropoiesis	NULL
.	NULL

Because	NULL
phosphorylation	NULL
of	NULL
MAPK	NULL
is	NULL
absolutely	NULL
required	NULL
for	NULL
its	NULL
activation	NULL
,	NULL
we	NULL
used	NULL
a	NULL
phospho-specific	NULL
MAPK	NULL
antibody	NULL
that	NULL
only	NULL
recognizes	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
the	NULL
enzyme	NULL
to	NULL
determine	NULL
its	NULL
activation	NULL
.	NULL

Figure	NULL
2A	NULL
illustrates	NULL
the	NULL
time	NULL
course	NULL
of	NULL
the	NULL
activation	NULL
.	NULL

When	NULL
serum-starved	NULL
ECFCs	NULL
were	NULL
treated	NULL
with	NULL
EPO	NULL
or	NULL
SCF	NULL
alone	NULL
,	NULL
marginal	NULL
MAPK	NULL
phosphorylation	NULL
was	NULL
observed	NULL
.	NULL

The	NULL
phosphorylation	NULL
induced	NULL
by	NULL
SCF	NULL
or	NULL
EPO	NULL
appeared	NULL
after	NULL
5	NULL
minutes	NULL
,	NULL
reached	NULL
a	NULL
peak	NULL
at	NULL
10	NULL
minutes	NULL
,	NULL
and	NULL
then	NULL
declined	NULL
slowly	NULL
thereafter	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
minimal	NULL
phosphorylation	NULL
of	NULL
MAPK	NULL
induced	NULL
by	NULL
EPO	NULL
or	NULL
SCF	NULL
alone	NULL
,	NULL
a	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

SYNERGISTIC	NULL
ACTIVATION	NULL
OF	NULL
MAPK	NULL
BY	NULL
EPO	NULL
AND	NULL
SCF	NULL
A	NULL
1145	NULL
5°	NULL
10°	NULL
20°	NULL
30°	NULL
60°	NULL
Blot	NULL
scr	NULL
awn	NULL
wor	NULL
wan	NULL
am	NULL
&	NULL
ETC	NULL
]	NULL
--	NULL
Phospho-MAPK	NULL
Ab	NULL
M	NULL
aat	NULL
Eile	NULL
!	NULL

-+	NULL
MAPK	NULL
Ab	NULL
Ero	NULL
Ey	NULL
as	NULL
I	NULL
&	NULL
f	NULL
ENC	NULL
-	NULL
}	NULL
-	NULL
Phospho-MAPK	NULL
Ab	NULL
&	NULL
assem	NULL
+	NULL
**	NULL
SCF+EPO	NULL
B	NULL
SCF	NULL
EPO	NULL
SCF+EPO	NULL
Fig	NULL
2	NULL
.	NULL

Synergistic	NULL
effects	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
on	NULL
phosphorylation	NULL
of	NULL
MAPK	NULL
(	NULL
ERK1	NULL
and	NULL
ERK2	NULL
)	NULL
(	NULL
A	NULL
)	NULL
and	NULL
MEK	NULL
(	NULL
B	NULL
)	NULL
and	NULL
on	NULL
stimulation	NULL
of	NULL
MAPK	NULL
activity	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Serum-starved	NULL
ECFC	NULL
were	NULL
treated	NULL
with	NULL
SCF	NULL
,	NULL
EPO	NULL
,	NULL
or	NULL
SCF	NULL
+	NULL
EPO	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
time	NULL
.	NULL

Whole	NULL
cell	NULL
extracts	NULL
(	NULL
20	NULL
ug	NULL
protein	NULL
)	NULL
were	NULL
subject	NULL
to	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blot	NULL
analyses	NULL
with	NULL
anti-phospho-M	NULL
APK	NULL
(	NULL
A	NULL
)	NULL
or	NULL
anti-phospho-MEK	NULL
(	NULL
B	NULL
)	NULL
antibodies	NULL
.	NULL

(	NULL
C	NULL
)	NULL
For	NULL
determination	NULL
of	NULL
MAPK	NULL
activity	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
10	NULL
minutes	NULL
with	NULL
SCF	NULL
,	NULL
EPO	NULL
,	NULL
or	NULL
SCF	NULL
+	NULL
EPO	NULL
and	NULL
whole	NULL
cell	NULL
extracts	NULL
containing	NULL
about	NULL
60	NULL
ug	NULL
of	NULL
total	NULL
protein	NULL
were	NULL
subjected	NULL
to	NULL
immunoprecipitation	NULL
with	NULL
anti-phospho-M	NULL
APK	NULL
.	NULL

The	NULL
MAPK	NULL
activities	NULL
in	NULL
the	NULL
immunoprecipitates	NULL
were	NULL
analyzed	NULL
by	NULL
using	NULL
myelin	NULL
basic	NULL
protein	NULL
as	NULL
a	NULL
substrate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
y-*°P	NULL
]	NULL
-ATP	NULL
in	NULL
buffer	NULL
A	NULL
containing	NULL
PKI	NULL
peptide	NULL
and	NULL
calmidi-zolium	NULL
,	NULL
inhibitors	NULL
of	NULL
PKA	NULL
and	NULL
PKC	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
representative	NULL
figure	NULL
from	NULL
four	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
show	NULL
n.	NULL
Each	NULL
experiment	NULL
was	NULL
performed	NULL
with	NULL
blood	NULL
samples	NULL
from	NULL
different	NULL
normal	NULL
volunteers	NULL
.	NULL

combination	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
gave	NULL
rise	NULL
to	NULL
markedly	NULL
enhanced	NULL
MAPK	NULL
phosphorylation	NULL
.	NULL

The	NULL
phosphorylation	NULL
appeared	NULL
within	NULL
5	NULL
minutes	NULL
,	NULL
reached	NULL
a	NULL
maximum	NULL
at	NULL
10	NULL
minutes	NULL
,	NULL
and	NULL
then	NULL
decreased	NULL
gradually	NULL
with	NULL
detectable	NULL
phosphorylation	NULL
remaining	NULL
at	NULL
60	NULL
minutes	NULL
.	NULL

Densitometric	NULL
analyses	NULL
indicated	NULL
that	NULL
the	NULL
level	NULL
of	NULL
MAPK	NULL
phosphorylation	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
was	NULL
at	NULL
least	NULL
10-fold	NULL
higher	NULL
than	NULL
the	NULL
combined	NULL
value	NULL
obtained	NULL
when	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
SCF	NULL
and	NULL
EPO	NULL
separately	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
Western	NULL
blot	NULL
analyses	NULL
with	NULL
antibodies	NULL
to	NULL
regular	NULL
anti-MAPK	NULL
antibody	NULL
showed	NULL
that	NULL
the	NULL
protein	NULL
levels	NULL
of	NULL
MAPK	NULL
in	NULL
the	NULL
cells	NULL
were	NULL
not	NULL
altered	NULL
by	NULL
the	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
a	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
by	NULL
SCF	NULL
and	NULL
EPO	NULL
.	NULL

f	NULL
``	NULL
a	NULL
z	NULL
;	NULL
=	NULL
&	NULL
ENC	NULL
)	NULL
-+-	NULL
Phospho-	NULL
MAPK	NULL
Ab	NULL
-g	NULL
Erk-1	NULL
Ema	NULL
]	NULL
-	NULL
MAPK	NULL
Ab	NULL
0	NULL
5	NULL
'	NULL
10°	NULL
20°	NULL
30°	NULL
60°	NULL
-asg-	NULL
MEK1/2	NULL
_	NULL
Phospho-MEK1/2	NULL
Ab	NULL
MEK1/2	NULL
Ab	NULL
tre	NULL
e	NULL
+	NULL
w	NULL
-a-	NULL
MEK1/2	NULL
-	NULL
Phospho-MEK1/2	NULL
Ab	NULL
MEK1/2	NULL
Ab	NULL
ca	NULL
-	NULL
afte	NULL
f	NULL
As	NULL
am	NULL
»	NULL
age	NULL
a	NULL
»	NULL
amp	NULL
at	NULL
-G-	NULL
MEK1/2	NULL
®	NULL
O0	NULL
&	NULL
&	NULL
ww	NULL
_	NULL
-gg-	NULL
MEK1/2	NULL
_	NULL
Phospho-MEK1/2	NULL
Ab	NULL
*-	NULL
a	NULL
»	NULL
as	NULL
e	NULL
»	NULL
a	NULL
»	NULL
am	NULL
-a-	NULL
MEK1/2	NULL
-	NULL
MEK1/2	NULL
Ab	NULL
4	NULL
§	NULL
a-o	NULL
O	NULL
&	NULL
o	NULL
x	NULL
2	NULL
2	NULL
B	NULL
ia	NULL
C	NULL
vo	NULL
1	NULL
J	NULL
a	NULL
.	NULL

<	NULL
p33	NULL
0	NULL
CS	NULL
xo	NULL
&	NULL
do	NULL
60	NULL
&	NULL
G	NULL
<	NULL
*	NULL
G	NULL
90	NULL
We	NULL
further	NULL
measured	NULL
the	NULL
activation	NULL
of	NULL
MEK	NULL
,	NULL
a	NULL
protein	NULL
kinase	NULL
responsible	NULL
for	NULL
activation	NULL
of	NULL
MAPK	NULL
.	NULL

Because	NULL
MEK	NULL
also	NULL
requires	NULL
phosphorylation	NULL
to	NULL
be	NULL
activated	NULL
,	NULL
we	NULL
used	NULL
a	NULL
phospho-MEK-specific	NULL
antibody	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
EPO	NULL
or	NULL
SCF	NULL
alone	NULL
induced	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
MEK	NULL
phosphorylation	NULL
,	NULL
whereas	NULL
a	NULL
combination	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
induced	NULL
synergistic	NULL
MEK	NULL
phosphorylation	NULL
(	NULL
Fig	NULL
2B	NULL
)	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
that	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
was	NULL
mediated	NULL
through	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
MEK	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
phospho-specific	NULL
antibodies	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
activity	NULL
of	NULL
MAPK	NULL
by	NULL
using	NULL
myelin	NULL
basic	NULL
protein	NULL
as	NULL
a	NULL
substrate	NULL
.	NULL
``	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
MAPK	NULL
was	NULL
first	NULL
immunoprecipitated	NULL
with	NULL
anti-phospho-	NULL
MAPK	NULL
and	NULL
its	NULL
kinase	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1146	NULL
A	NULL
-	NULL
Inhibitors	NULL
Control	NULL
PD98059	NULL
Wortmannin	NULL
Blot	NULL
:	NULL
SUI	NULL
ET	NULL
AL	NULL
Fig	NULL
3	NULL
.	NULL

MEK	NULL
inhibitor	NULL
PD98059	NULL
and	NULL
PI-3	NULL
kinase	NULL
inhibitor	NULL
wortman-	NULL
Erk1	NULL
-g	NULL
Tus	NULL
ames	NULL
Erk2	NULL
-It	NULL
»	NULL
l	NULL
mug	NULL
4	NULL
Erk1	NULL
-pe	NULL
-	NULL
®	NULL
hae	NULL
.	NULL

woe	NULL
mate	NULL
|	NULL
I	NULL
Erk2	NULL
-	NULL
»	NULL
ce	NULL
”	NULL
nu	NULL
”	NULL
,	NULL
nin	NULL
inhibit	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
(	NULL
A	NULL
)	NULL
and	NULL
cell	NULL
growth	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Serum-starved	NULL
cells	NULL
were	NULL
left	NULL
e	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
or	NULL
pretreated	NULL
MAPK	NULL
Ab	NULL
with	NULL
100	NULL
mmol/L	NULL
PD98059	NULL
or	NULL
0.5	NULL
wmol/	NULL
L	NULL
wortmannin	NULL
for	NULL
1	NULL
hour	NULL
and	NULL
Phospho-MAPK	NULL
Ab	NULL
Factors	NULL
120	NULL
then	NULL
stimulated	NULL
with	NULL
SCF	NULL
and	NULL
EPO	NULL
separately	NULL
or	NULL
jointly	NULL
for	NULL
10	NULL
minutes	NULL
.	NULL

Whole	NULL
cell	NULL
extracts	NULL
were	NULL
subject	NULL
to	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blotting	NULL
with	NULL
phospho-specific	NULL
MAPK	NULL
antibody	NULL
or	NULL
anti-MAPK	NULL
antibody	NULL
.	NULL

{	NULL
1	NULL
B	NULL
-o-	NULL
ero	NULL
1007	NULL
-	NULL
@	NULL
-	NULL
_	NULL
SCF+EPO	NULL
c	NULL
O	NULL
1	NULL
a	NULL
Colony	NULL
Number	NULL
(	NULL
%	NULL
of	NULL
control	NULL
)	NULL
$	NULL
o	NULL
TOTP	NULL
to	NULL
el	NULL
1	NULL
C	NULL
-o-	NULL
Ero	NULL
-	NULL
#	NULL
-	NULL
_	NULL
The	NULL
latter	NULL
detects	NULL
both	NULL
phosphorylated	NULL
and	NULL
nonphosphorylated	NULL
MAPK	NULL
.	NULL

A	NULL
representative	NULL
figure	NULL
from	NULL
four	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

Each	NULL
experiment	NULL
was	NULL
performed	NULL
with	NULL
blood	NULL
samples	NULL
from	NULL
different	NULL
normal	NULL
volunteers	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
a	NULL
nonspecific	NULL
band	NULL
right	NULL
below	NULL
phospho-Erk2	NULL
was	NULL
equally	NULL
distributed	NULL
in	NULL
all	NULL
lanes	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
inhibitors	NULL
on	NULL
erythroid	NULL
cell	NULL
growth	NULL
,	NULL
day-6	NULL
ECFC	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
allowed	NULL
to	NULL
grow	NULL
for	NULL
another	NULL
7	NULL
days	NULL
in	NULL
liquid	NULL
medium	NULL
supplemented	NULL
with	NULL
EPO	NULL
(	NULL
0	NULL
)	NULL
or	NULL
SCF	NULL
+	NULL
EPO	NULL
(	NULL
@	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
varying	NULL
concentra-	NULL
0	NULL
so	NULL
-	NULL
100	NULL
2	NULL
.	NULL

Concentration	NULL
00	NULL
O0	NULL
0.1	NULL
os	NULL
1.0	NULL
(	NULL
#	NULL
M	NULL
)	NULL
tions	NULL
of	NULL
PD98059	NULL
(	NULL
B	NULL
)	NULL
or	NULL
wortmannin	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Cell	NULL
numbers	NULL
were	NULL
determined	NULL
after	NULL
7	NULL
days	NULL
in	NULL
culture	NULL
.	NULL

PD98059	NULL
activity	NULL
was	NULL
assayed	NULL
in	NULL
liquid-solid	NULL
reaction	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
MAPK	NULL
phosphorylation	NULL
,	NULL
the	NULL
combined	NULL
treatment	NULL
of	NULL
ECFCs	NULL
with	NULL
SCF	NULL
and	NULL
EPO	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
markedly	NULL
enhanced	NULL
MAPK	NULL
activity	NULL
,	NULL
fourfold	NULL
to	NULL
sixfold	NULL
greater	NULL
than	NULL
that	NULL
observed	NULL
when	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
SCF	NULL
or	NULL
EPO	NULL
alone	NULL
(	NULL
Fig	NULL
2C	NULL
)	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
synergy	NULL
is	NULL
less	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
anti-phospho-MAPK	NULL
antibodies	NULL
,	NULL
but	NULL
this	NULL
could	NULL
be	NULL
due	NULL
to	NULL
a	NULL
lesser	NULL
efficiency	NULL
of	NULL
the	NULL
liquid-solid	NULL
phase	NULL
reaction	NULL
for	NULL
activity	NULL
assays	NULL
.	NULL

Collectively	NULL
,	NULL
the	NULL
data	NULL
indicate	NULL
that	NULL
SCF	NULL
and	NULL
EPO	NULL
synergistically	NULL
stimulate	NULL
MAPK	NULL
activation	NULL
by	NULL
inducing	NULL
signifi-cant	NULL
,	NULL
greater-than-additive	NULL
increases	NULL
in	NULL
both	NULL
MAPK	NULL
phosphorylation	NULL
and	NULL
kinase	NULL
activity	NULL
.	NULL

Because	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
correlates	NULL
with	NULL
the	NULL
synergistic	NULL
effect	NULL
on	NULL
cell	NULL
growth	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
the	NULL
synergistic	NULL
effect	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
on	NULL
erythropoiesis	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
.	NULL

PD98059	NULL
(	NULL
MEK1/2	NULL
inhibitor	NULL
)	NULL
and	NULL
Wortmannin	NULL
(	NULL
PI-3	NULL
kinase	NULL
inhibitor	NULL
)	NULL
affect	NULL
MAPK	NULL
activation	NULL
and	NULL
cell	NULL
growth	NULL
induced	NULL
by	NULL
SCF	NULL
and	NULL
EPO	NULL
.	NULL

To	NULL
prove	NULL
further	NULL
the	NULL
importance	NULL
of	NULL
MAPK	NULL
activation	NULL
in	NULL
erythropoiesis	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
PD98059	NULL
,	NULL
which	NULL
acts	NULL
as	NULL
a	NULL
highly	NULL
selected	NULL
inhibitor	NULL
of	NULL
MEK	NULL
,	NULL
on	NULL
MAPK	NULL
activation	NULL
and	NULL
cell	NULL
growth	NULL
induced	NULL
by	NULL
SCF	NULL
and	NULL
EPO	NULL
.	NULL

Pretreatment	NULL
of	NULL
cells	NULL
with	NULL
100	NULL
umol/L	NULL
PD98059	NULL
completely	NULL
inhibited	NULL
activation	NULL
of	NULL
MAPK	NULL
induced	NULL
by	NULL
EPO	NULL
and	NULL
SCF	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

Concomitantly	NULL
,	NULL
PD98059	NULL
treatment	NULL
also	NULL
dose-dependently	NULL
inhibited	NULL
growth	NULL
of	NULL
ECFC	NULL
in	NULL
suspension	NULL
culture	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
was	NULL
observed	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
50	NULL
umol/L	NULL
,	NULL
and	NULL
at	NULL
200	NULL
umol/L	NULL
,	NULL
greater	NULL
than	NULL
70	NULL
%	NULL
inhibition	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
3B	NULL
)	NULL
.	NULL

In	NULL
Wortmannin	NULL
Results	NULL
represent	NULL
data	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

an	NULL
attempt	NULL
to	NULL
show	NULL
the	NULL
mechanism	NULL
controlling	NULL
MAPK	NULL
activation	NULL
by	NULL
SCF	NULL
and	NULL
EPO	NULL
,	NULL
we	NULL
also	NULL
treated	NULL
the	NULL
cells	NULL
with	NULL
wortmannin	NULL
,	NULL
a	NULL
PI-3	NULL
kinase	NULL
inhibitor	NULL
.	NULL

Wortmannin	NULL
markedly	NULL
inhibited	NULL
the	NULL
activation	NULL
of	NULL
MAPK	NULL
induced	NULL
by	NULL
EPO	NULL
but	NULL
had	NULL
no	NULL
inhibitory	NULL
effect	NULL
on	NULL
that	NULL
induced	NULL
by	NULL
SCF	NULL
alone	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
reduced	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
phosphorylation	NULL
by	NULL
SCF	NULL
and	NULL
EPO	NULL
to	NULL
a	NULL
level	NULL
similar	NULL
to	NULL
that	NULL
attained	NULL
with	NULL
SCF	NULL
alone	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
10	NULL
,	NULL
and	NULL
12	NULL
,	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
a	NULL
nonspecific	NULL
band	NULL
right	NULL
below	NULL
phospho-Erk2	NULL
was	NULL
equally	NULL
distributed	NULL
in	NULL
all	NULL
lanes	NULL
.	NULL

Accordingly	NULL
,	NULL
wortmannin	NULL
also	NULL
markedly	NULL
inhibited	NULL
EPO	NULL
,	NULL
but	NULL
not	NULL
SCF-induced	NULL
MEK	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
PI-3	NULL
kinase	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
EPO-	NULL
but	NULL
not	NULL
in	NULL
SCF-mediated	NULL
MAPK	NULL
activation	NULL
and	NULL
that	NULL
SCF	NULL
and	NULL
EPO	NULL
may	NULL
activate	NULL
MAPK	NULL
through	NULL
different	NULL
pathways	NULL
.	NULL

The	NULL
insensitivity	NULL
of	NULL
SCF-induced	NULL
MAPK	NULL
activation	NULL
to	NULL
wortmannin	NULL
also	NULL
suggests	NULL
that	NULL
SCF	NULL
does	NULL
not	NULL
transduce	NULL
EPO-R-mediated	NULL
MAPK	NULL
activation	NULL
,	NULL
although	NULL
it	NULL
causes	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
EPO-R.	NULL
As	NULL
expected	NULL
,	NULL
pretreatment	NULL
of	NULL
ECFC	NULL
with	NULL
wortmannin	NULL
also	NULL
inhibited	NULL
the	NULL
growth	NULL
of	NULL
ECFC	NULL
in	NULL
liquid	NULL
medium	NULL
cultures	NULL
,	NULL
although	NULL
the	NULL
degree	NULL
of	NULL
inhibition	NULL
was	NULL
slightly	NULL
lower	NULL
compared	NULL
with	NULL
that	NULL
exhibited	NULL
by	NULL
PD98059	NULL
(	NULL
Fig	NULL
3C	NULL
)	NULL
.	NULL

While	NULL
Fig	NULL
3	NULL
demonstrated	NULL
the	NULL
inhibition	NULL
of	NULL
ECFC	NULL
growth	NULL
in	NULL
suspension	NULL
culture	NULL
,	NULL
similar	NULL
results	NULL
were	NULL
also	NULL
obtained	NULL
with	NULL
erythroid	NULL
colony	NULL
formation	NULL
assays	NULL
in	NULL
semisolid	NULL
medium	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
by	NULL
SCF	NULL
and	NULL
EPO	NULL
plays	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
the	NULL
proliferation	NULL
and	NULL
maturation	NULL
of	NULL
human	NULL
erythroid	NULL
progenitors	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

SYNERGISTIC	NULL
ACTIVATION	NULL
OF	NULL
MAPK	NULL
BY	NULL
EPO	NULL
AND	NULL
SCF	NULL
A	NULL
Lanes	NULL
1	NULL
20	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
Time	NULL
{	NULL
min	NULL
)	NULL
0	NULL
30	NULL
5	NULL
10	NULL
30	NULL
5	NULL
10	NULL
30	NULL
5	NULL
10	NULL
30	NULL
10	NULL
**	NULL
-	NULL
wcw	NULL
nt	NULL
he	NULL
coe	NULL
e	NULL
can	NULL
%	NULL
#	NULL
e	NULL
+	NULL
Factors	NULL
-	NULL
pros	NULL
3	NULL
<	NULL
o	NULL
6	NULL
3	NULL
§	NULL
P	NULL
&	NULL
&	NULL
4	NULL
&	NULL
£	NULL
&	NULL
5	NULL
B	NULL
Lanes	NULL
10	NULL
2	NULL
3	NULL
4	NULL
50060	NULL
708	NULL
Time	NULL
(	NULL
min	NULL
}	NULL
10	NULL
60	NULL
10	NULL
60	NULL
10	NULL
60	NULL
10	NULL
60	NULL
W	NULL
--	NULL
tt	NULL
=	NULL
»	NULL
wth	NULL
mn	NULL
Factors	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
SCF	NULL
and	NULL
inhibitors	NULL
of	NULL
MEK	NULL
and	NULL
PI-3	NULL
kinase	NULL
have	NULL
no	NULL
effects	NULL
on	NULL
EPO-induced	NULL
activation	NULL
of	NULL
STATS	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Serum-starved	NULL
day-8	NULL
ECFC	NULL
were	NULL
treated	NULL
with	NULL
SCF	NULL
,	NULL
EPO	NULL
,	NULL
or	NULL
SCF	NULL
+	NULL
EPO	NULL
for	NULL
5	NULL
,	NULL
10	NULL
,	NULL
and	NULL
30	NULL
minutes	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
extracted	NULL
and	NULL
analyzed	NULL
for	NULL
STAT	NULL
activity	NULL
with	NULL
a	NULL
``	NULL
P-labeled	NULL
PIE	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

EPO®*	NULL
(	NULL
lane	NULL
12	NULL
,	NULL
A	NULL
)	NULL
denotes	NULL
a	NULL
supershift	NULL
analysis	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
preincubated	NULL
with	NULL
anti-STAT5b	NULL
antibody	NULL
(	NULL
0.2	NULL
mg	NULL
)	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
PIE	NULL
probe	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Serum-starved	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
100	NULL
mol/L	NULL
PD98059	NULL
or	NULL
0.5	NULL
pmol/L	NULL
wortmannin	NULL
for	NULL
1	NULL
hour	NULL
before	NULL
stimulation	NULL
with	NULL
EPO	NULL
for	NULL
10	NULL
and	NULL
60	NULL
minutes	NULL
.	NULL

STATS	NULL
activity	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
above	NULL
.	NULL

SCF	NULL
has	NULL
no	NULL
effects	NULL
on	NULL
EPO-induced	NULL
STAT	NULL
activation	NULL
in	NULL
human	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

-	NULL
Activation	NULL
of	NULL
STAT	NULL
family	NULL
transcription	NULL
factors	NULL
is	NULL
another	NULL
major	NULL
signal	NULL
transduction	NULL
pathway	NULL
involved	NULL
in	NULL
the	NULL
action	NULL
of	NULL
growth	NULL
factor	NULL
and	NULL
cytokines	NULL
.	NULL
``	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
EPO	NULL
activates	NULL
STAT1	NULL
and	NULL
whereas	NULL
SCF	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
STAT3	NULL
or	NULL
STATS5	NULL
activa-tion	NULL
.	NULL
``	NULL

''	NULL
To	NULL
examine	NULL
whether	NULL
activation	NULL
of	NULL
STAT	NULL
's	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
synergistic	NULL
action	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
in	NULL
erythropoiesis	NULL
,	NULL
we	NULL
analyzed	NULL
STAT	NULL
activity	NULL
by	NULL
using	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
with	NULL
specific	NULL
DNA	NULL
probes	NULL
.	NULL
``	NULL

With	NULL
hSIE	NULL
,	NULL
a	NULL
high-affinity	NULL
mutant	NULL
form	NULL
of	NULL
the	NULL
serum-inducible	NULL
element	NULL
widely	NULL
used	NULL
to	NULL
detect	NULL
STAT1	NULL
and	NULL
STAT3	NULL
,	NULL
``	NULL
*°	NULL
no	NULL
binding	NULL
was	NULL
observed	NULL
after	NULL
stimulation	NULL
of	NULL
cells	NULL
with	NULL
SCF	NULL
and	NULL
EPO	NULL
.	NULL

With	NULL
PIE	NULL
,	NULL
a	NULL
prolactin-inducible	NULL
element	NULL
that	NULL
can	NULL
specifically	NULL
bind	NULL
STAT5a	NULL
and	NULL
STAT5b	NULL
,	NULL
``	NULL
stimulation	NULL
of	NULL
ECFCs	NULL
with	NULL
EPO	NULL
induced	NULL
marked	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
4A	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
STATS	NULL
in	NULL
the	NULL
DNA-protein	NULL
complex	NULL
is	NULL
evident	NULL
in	NULL
the	NULL
super-shift	NULL
analyses	NULL
1147	NULL
with	NULL
anti-STATS5	NULL
antibody	NULL
(	NULL
Fig	NULL
4A	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

EPO-induced	NULL
STATS	NULL
activation	NULL
was	NULL
detected	NULL
after	NULL
5	NULL
minutes	NULL
of	NULL
incubation	NULL
and	NULL
remained	NULL
at	NULL
30	NULL
minutes	NULL
.	NULL

SCF	NULL
alone	NULL
failed	NULL
to	NULL
stimulate	NULL
any	NULL
STATS	NULL
activity	NULL
and	NULL
addition	NULL
of	NULL
SCF	NULL
to	NULL
EPO	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
EPO-induced	NULL
STATS	NULL
activation	NULL
.	NULL

This	NULL
again	NULL
suggests	NULL
that	NULL
,	NULL
although	NULL
SCF	NULL
causes	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
,	NULL
it	NULL
can	NULL
not	NULL
transduce	NULL
a	NULL
signal	NULL
through	NULL
the	NULL
receptor	NULL
.	NULL

PD98059	NULL
and	NULL
wortmannin	NULL
,	NULL
which	NULL
displayed	NULL
marked	NULL
effects	NULL
on	NULL
cell	NULL
growth	NULL
and	NULL
MAPK	NULL
activation	NULL
,	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
EPO-induced	NULL
STATS	NULL
activation	NULL
,	NULL
suggesting	NULL
that	NULL
MAPK	NULL
and	NULL
PI-3	NULL
kinase	NULL
may	NULL
not	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
EPO-dependent	NULL
STATS	NULL
activation	NULL
.	NULL

These	NULL
experiments	NULL
indicate	NULL
that	NULL
activation	NULL
of	NULL
STATS5	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
synergistic	NULL
effect	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
both	NULL
STAT5a	NULL
and	NULL
STAT5b	NULL
knock-outs	NULL
did	NULL
not	NULL
show	NULL
any	NULL
abnormalities	NULL
of	NULL
erythropoiesis	NULL
suggests	NULL
that	NULL
STAT5	NULL
may	NULL
not	NULL
be	NULL
important	NULL
for	NULL
erythropoiesis	NULL
in	NULL
vivo	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
However	NULL
,	NULL
because	NULL
of	NULL
the	NULL
possible	NULL
redundancy	NULL
between	NULL
STAT	NULL
5a	NULL
and	NULL
STAT	NULL
5b	NULL
,	NULL
double	NULL
knock-out	NULL
mice	NULL
of	NULL
STAT	NULL
5a	NULL
and	NULL
STAT	NULL
5b	NULL
need	NULL
to	NULL
be	NULL
generated	NULL
to	NULL
test	NULL
the	NULL
role	NULL
of	NULL
STATS	NULL
in	NULL
erythropoiesis	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
SCF	NULL
and	NULL
EPO	NULL
synergistically	NULL
activate	NULL
MAPK	NULL
,	NULL
which	NULL
correlates	NULL
with	NULL
their	NULL
effects	NULL
on	NULL
erythroid	NULL
cell	NULL
growth	NULL
,	NULL
thus	NULL
providing	NULL
an	NULL
intracellular	NULL
mechanism	NULL
for	NULL
the	NULL
synergistic	NULL
action	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
in	NULL
erythropoiesis	NULL
.	NULL

Our	NULL
data	NULL
also	NULL
suggest	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
produced	NULL
by	NULL
SCF	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
transduce	NULL
the	NULL
EPO	NULL
signal	NULL
,	NULL
which	NULL
is	NULL
evident	NULL
in	NULL
the	NULL
failure	NULL
of	NULL
SCF	NULL
to	NULL
induce	NULL
wortmannin-sensitive	NULL
MAPK	NULL
activation	NULL
and	NULL
activation	NULL
of	NULL
STAT5	NULL
.	NULL

SCF	NULL
may	NULL
cause	NULL
phosphorylation	NULL
of	NULL
EPO-R	NULL
at	NULL
sites	NULL
that	NULL
are	NULL
not	NULL
essential	NULL
for	NULL
signal	NULL
transduction	NULL
.	NULL

MAPK	NULL
lies	NULL
at	NULL
a	NULL
convergent	NULL
point	NULL
for	NULL
many	NULL
signaling	NULL
events	NULL
.	NULL

It	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
promoting	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
``	NULL
?	NULL

and	NULL
preventing	NULL
apoptosis	NULL
.	NULL
``	NULL

The	NULL
inhibition	NULL
of	NULL
erythroid	NULL
cell	NULL
growth	NULL
and	NULL
colony	NULL
formation	NULL
by	NULL
inhibitors	NULL
of	NULL
MEK	NULL
and	NULL
PI-3	NULL
kinase	NULL
demonstrate	NULL
the	NULL
crucial	NULL
role	NULL
of	NULL
MAPK	NULL
in	NULL
the	NULL
SCF-	NULL
and	NULL
EPO-mediated	NULL
erythropoiesis	NULL
.	NULL

Both	NULL
the	NULL
magnitude	NULL
and	NULL
duration	NULL
of	NULL
the	NULL
activation	NULL
are	NULL
crucial	NULL
,	NULL
and	NULL
studies	NULL
suggest	NULL
that	NULL
transient	NULL
activation	NULL
of	NULL
MAPK	NULL
may	NULL
trigger	NULL
prolifera-tion	NULL
,	NULL
whereas	NULL
sustained	NULL
activation	NULL
allows	NULL
differentiation	NULL
.	NULL
``	NULL

The	NULL
synergistic	NULL
effects	NULL
of	NULL
SCF	NULL
and	NULL
EPO	NULL
observed	NULL
in	NULL
our	NULL
current	NULL
study	NULL
not	NULL
only	NULL
greatly	NULL
enhanced	NULL
the	NULL
magnitude	NULL
,	NULL
but	NULL
also	NULL
enhanced	NULL
the	NULL
duration	NULL
of	NULL
the	NULL
activation	NULL
,	NULL
which	NULL
may	NULL
be	NULL
important	NULL
for	NULL
both	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
erythroid	NULL
cells	NULL
.	NULL

Prolonged	NULL
activation	NULL
of	NULL
MAPK	NULL
might	NULL
also	NULL
play	NULL
a	NULL
role	NULL
in	NULL
preventing	NULL
apoptosis	NULL
,	NULL
as	NULL
reported	NULL
in	NULL
rat	NULL
pheochromocytoma	NULL
PC12	NULL
cells	NULL
.	NULL
``	NULL

Prevention	NULL
of	NULL
apoptosis	NULL
is	NULL
believed	NULL
to	NULL
be	NULL
the	NULL
primary	NULL
role	NULL
for	NULL
EPO	NULL
.	NULL
``	NULL

Although	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
has	NULL
been	NULL
previously	NULL
observed	NULL
in	NULL
various	NULL
cell	NULL
lines	NULL
when	NULL
treated	NULL
with	NULL
insulin	NULL
and	NULL
phorbol	NULL
ester	NULL
,	NULL
``	NULL
integrins	NULL
and	NULL
growth	NULL
factors	NULL
,	NULL
``	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
and	NULL
SCF	NULL
,	NULL
``	NULL
or	NULL
interleukin-3	NULL
(	NULL
IL-3	NULL
)	NULL
and	NULL
SCF	NULL
,	NULL
``	NULL
the	NULL
degree	NULL
of	NULL
the	NULL
synergistic	NULL
effects	NULL
was	NULL
not	NULL
as	NULL
significant	NULL
as	NULL
we	NULL
observed	NULL
with	NULL
SCF	NULL
and	NULL
EPO	NULL
in	NULL
the	NULL
primary	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
this	NULL
study	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
correlate	NULL
directly	NULL
the	NULL
synergy	NULL
in	NULL
signal	NULL
transduction	NULL
with	NULL
the	NULL
synergy	NULL
in	NULL
cell	NULL
growth	NULL
.	NULL

Considering	NULL
that	NULL
hematopoiesis	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
multiple	NULL
growth	NULL
factors	NULL
or	NULL
cytokines	NULL
,	NULL
this	NULL
study	NULL
begins	NULL
to	NULL
show	NULL
how	NULL
these	NULL
growth	NULL
factors	NULL
and	NULL
cytokines	NULL
interact	NULL
to	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1148	NULL
produce	NULL
balanced	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

It	NULL
also	NULL
suggests	NULL
that	NULL
the	NULL
synergistic	NULL
effects	NULL
of	NULL
other	NULL
growth	NULL
factors	NULL
and	NULL
cytokines	NULL
in	NULL
other	NULL
tissue	NULL
systems	NULL
may	NULL
be	NULL
mediated	NULL
through	NULL
synergistic	NULL
activation	NULL
of	NULL
MAPK	NULL
.	NULL

The	NULL
general	NULL
scheme	NULL
of	NULL
the	NULL
MAPK	NULL
activation	NULL
pathway	NULL
includes	NULL
a	NULL
series	NULL
of	NULL
protein	NULL
phosphorylations	NULL
and	NULL
protein-protein	NULL
interactions	NULL
involving	NULL
,	NULL
sequentially	NULL
,	NULL
Grb2	NULL
,	NULL
mSOS	NULL
,	NULL
Ras	NULL
,	NULL
Raf-1	NULL
,	NULL
MEK	NULL
,	NULL
and	NULL
MAPK	NULL
.	NULL

SCF	NULL
transduces	NULL
its	NULL
signal	NULL
by	NULL
binding	NULL
to	NULL
its	NULL
receptor	NULL
c-Kit	NULL
,	NULL
a	NULL
PDGF	NULL
family	NULL
receptor	NULL
tyrosine	NULL
kinase	NULL
,	NULL
and	NULL
,	NULL
thus	NULL
,	NULL
presumably	NULL
,	NULL
it	NULL
activates	NULL
MAPK	NULL
via	NULL
the	NULL
Ras/Raf	NULL
pathway	NULL
.	NULL
``	NULL

However	NULL
,	NULL
for	NULL
EPO	NULL
,	NULL
direct	NULL
recruitment	NULL
of	NULL
Grb2	NULL
to	NULL
EPO-R	NULL
has	NULL
not	NULL
been	NULL
reported	NULL
.	NULL

Although	NULL
phosphorylation	NULL
of	NULL
SHC	NULL
and	NULL
insulin	NULL
receptor	NULL
substrate-2	NULL
after	NULL
EPO	NULL
stimulation	NULL
might	NULL
provide	NULL
docking	NULL
sites	NULL
for	NULL
Grb2	NULL
binding,4~*	NULL
recent	NULL
studies	NULL
suggests	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
SHC/Grb2-independent	NULL
path-way	NULL
.	NULL

**	NULL
``	NULL
``	NULL
The	NULL
fact	NULL
that	NULL
the	NULL
PI-3	NULL
kinase	NULL
inhibitor	NULL
wortmannin	NULL
inhibited	NULL
EPO-induced	NULL
MAPK	NULL
activation	NULL
,	NULL
but	NULL
not	NULL
that	NULL
of	NULL
SCE	NULL
,	NULL
suggested	NULL
that	NULL
SCF	NULL
and	NULL
EPO	NULL
may	NULL
lead	NULL
to	NULL
activation	NULL
of	NULL
MAPK	NULL
through	NULL
different	NULL
pathways	NULL
.	NULL

Because	NULL
SCF	NULL
and	NULL
EPO	NULL
synergistically	NULL
activate	NULL
MEK	NULL
,	NULL
the	NULL
convergent	NULL
point	NULL
at	NULL
which	NULL
these	NULL
two	NULL
pathways	NULL
interact	NULL
should	NULL
be	NULL
at	NULL
the	NULL
level	NULL
of	NULL
MEK	NULL
or	NULL
above	NULL
MEK	NULL
.	NULL

Presumably	NULL
,	NULL
these	NULL
two	NULL
pathways	NULL
would	NULL
transduce	NULL
signals	NULL
that	NULL
act	NULL
on	NULL
different	NULL
sites	NULL
of	NULL
the	NULL
target	NULL
protein	NULL
to	NULL
facilitate	NULL
the	NULL
synergistic	NULL
effects	NULL
.	NULL

How	NULL
EPO	NULL
transduces	NULL
its	NULL
signal	NULL
through	NULL
PI-3	NULL
kinase	NULL
to	NULL
MAPK	NULL
is	NULL
still	NULL
unknown	NULL
.	NULL

It	NULL
has	NULL
been	NULL
postulated	NULL
that	NULL
protein	NULL
kinase	NULL
C	NULL
might	NULL
be	NULL
one	NULL
of	NULL
the	NULL
mediators	NULL
.	NULL
``	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
thank	NULL
Ella	NULL
Stitt	NULL
,	NULL
Judy	NULL
Luna	NULL
,	NULL
and	NULL
Amanda	NULL
Hodges	NULL
for	NULL
their	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Krantz	NULL
SB	NULL
:	NULL
Erythropoietin	NULL
.	NULL

Blood	NULL
77:419	NULL
,	NULL
1991	NULL
2	NULL
.	NULL

Metcalf	NULL
D	NULL
:	NULL
Hematopoietic	NULL
regulators	NULL
:	NULL
Redundancy	NULL
or	NULL
subtlety	NULL
?	NULL

Blood	NULL
82:3515	NULL
,	NULL
1993	NULL
3	NULL
.	NULL

Ogawa	NULL
M	NULL
:	NULL
Differentiation	NULL
and	NULL
proliferation	NULL
of	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
.	NULL

Blood	NULL
81:2844	NULL
,	NULL
1993	NULL
4	NULL
.	NULL

Chui	NULL
DH	NULL
,	NULL
Liao	NULL
SK	NULL
,	NULL
Walker	NULL
K	NULL
:	NULL
Fetal	NULL
erythropoiesis	NULL
in	NULL
steel	NULL
mutant	NULL
mice	NULL
.	NULL

III	NULL
.	NULL

Defect	NULL
in	NULL
differentiation	NULL
from	NULL
BFU-E	NULL
to	NULL
CFU-E	NULL
during	NULL
early	NULL
development	NULL
.	NULL

Blood	NULL
51:539	NULL
,	NULL
1978	NULL
5	NULL
.	NULL

Russell	NULL
ES	NULL
:	NULL
Hereditary	NULL
anemias	NULL
of	NULL
the	NULL
mouse	NULL
:	NULL
A	NULL
review	NULL
for	NULL
genetics	NULL
.	NULL

Adv	NULL
Genet	NULL
20:357	NULL
,	NULL
1979	NULL
6	NULL
.	NULL

Nocka	NULL
K	NULL
,	NULL
Majimber	NULL
S	NULL
,	NULL
Chabot	NULL
B	NULL
,	NULL
Ray	NULL
P	NULL
,	NULL
Cervone	NULL
M	NULL
,	NULL
Bernstein	NULL
A	NULL
,	NULL
Besmer	NULL
P	NULL
:	NULL
Expression	NULL
of	NULL
c-kif	NULL
gene	NULL
products	NULL
in	NULL
cellular	NULL
targets	NULL
of	NULL
W	NULL
mutations	NULL
in	NULL
normal	NULL
and	NULL
W	NULL
mutant	NULL
mice-evidence	NULL
for	NULL
an	NULL
impaired	NULL
c-kit	NULL
kinase	NULL
in	NULL
mutant	NULL
mice	NULL
.	NULL

Genes	NULL
Dev	NULL
3:816	NULL
,	NULL
1989	NULL
7	NULL
.	NULL

Wu	NULL
H	NULL
,	NULL
Liu	NULL
X	NULL
,	NULL
Jaenisch	NULL
R	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Generation	NULL
of	NULL
committed	NULL
erythoid	NULL
BFU-E	NULL
progenitors	NULL
does	NULL
not	NULL
require	NULL
erythropoietin	NULL
and	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

Cell	NULL
83:59	NULL
,	NULL
1995	NULL
8	NULL
.	NULL

McNiece	NULL
IK	NULL
,	NULL
Langleley	NULL
KE	NULL
,	NULL
Zsebo	NULL
KM	NULL
:	NULL
Recombinant	NULL
human	NULL
stem	NULL
cell	NULL
factor	NULL
synergies	NULL
with	NULL
GM-CSF	NULL
,	NULL
G-CSF	NULL
,	NULL
IL-3	NULL
and	NULL
EPO	NULL
to	NULL
stimulate	NULL
human	NULL
progenitor	NULL
cells	NULL
of	NULL
the	NULL
myeloid	NULL
and	NULL
erythroid	NULL
lineages	NULL
.	NULL

Exp	NULL
Hematol	NULL
19:226	NULL
,	NULL
1991	NULL
9	NULL
.	NULL

Muta	NULL
K	NULL
,	NULL
Krantz	NULL
SB	NULL
,	NULL
Bondurant	NULL
MC	NULL
,	NULL
Wickrema	NULL
A	NULL
:	NULL
Distinct	NULL
roles	NULL
of	NULL
erythropoietin	NULL
,	NULL
insulin-like	NULL
growth	NULL
factor	NULL
I	NULL
,	NULL
and	NULL
stem	NULL
cell	NULL
factor	NULL
in	NULL
the	NULL
development	NULL
of	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
94:34	NULL
,	NULL
1994	NULL
10	NULL
.	NULL

Sui	NULL
X	NULL
,	NULL
Tsuji	NULL
K	NULL
,	NULL
Tanaka	NULL
R	NULL
,	NULL
Muraoka	NULL
K	NULL
,	NULL
Ebihara	NULL
Y	NULL
,	NULL
Ikebuchi	NULL
K	NULL
,	NULL
Yasukawa	NULL
K	NULL
,	NULL
Taga	NULL
T	NULL
,	NULL
Kishimoto	NULL
T	NULL
,	NULL
Nakahata	NULL
T	NULL
:	NULL
Erythropoicetin-independent	NULL
erythrocyte	NULL
production	NULL
:	NULL
Signals	NULL
through	NULL
gp130	NULL
and	NULL
c-kit	NULL
dramatically	NULL
promote	NULL
erythropoiesis	NULL
from	NULL
human	NULL
CD34~*	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
183:837	NULL
,	NULL
1996	NULL
SUI	NULL
ET	NULL
AL	NULL
11	NULL
.	NULL

Wu	NULL
H	NULL
,	NULL
Klingmuller	NULL
U	NULL
,	NULL
Besmer	NULL
P	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Interactions	NULL
of	NULL
the	NULL
erythropoietin	NULL
and	NULL
stem-cell-factor	NULL
receptors	NULL
.	NULL

Nature	NULL
377:242	NULL
,	NULL
1995	NULL
12	NULL
.	NULL

Seger	NULL
R	NULL
,	NULL
Seger	NULL
D	NULL
,	NULL
Reszka	NULL
AA	NULL
,	NULL
Munar	NULL
ES	NULL
,	NULL
Eldar-Finkelman	NULL
H	NULL
,	NULL
Dobrowolska	NULL
G	NULL
,	NULL
Jensen	NULL
AM	NULL
,	NULL
Campbell	NULL
JS	NULL
,	NULL
Fischer	NULL
EH	NULL
,	NULL
Krebs	NULL
EG	NULL
:	NULL
Overexpression	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
kinase	NULL
(	NULL
MAPKK	NULL
)	NULL
and	NULL
its	NULL
mutants	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
.	NULL

Evidence	NULL
that	NULL
MAPKK	NULL
involvement	NULL
in	NULL
cellular	NULL
proliferation	NULL
is	NULL
regulated	NULL
by	NULL
phosphorylation	NULL
of	NULL
serine	NULL
residues	NULL
in	NULL
its	NULL
kinase	NULL
subdomains	NULL
VII	NULL
and	NULL
VIII	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:25699	NULL
,	NULL
1994	NULL
13	NULL
.	NULL

Sawada	NULL
K	NULL
,	NULL
Krantz	NULL
SB	NULL
,	NULL
Kans	NULL
JS	NULL
,	NULL
Dessypris	NULL
EN	NULL
,	NULL
Sawyer	NULL
S	NULL
,	NULL
Glick	NULL
AD	NULL
,	NULL
Civin	NULL
CI	NULL
:	NULL
Purification	NULL
of	NULL
human	NULL
erythroid	NULL
colony-forming	NULL
units	NULL
and	NULL
demonstration	NULL
of	NULL
specific	NULL
binding	NULL
of	NULL
erythropoietin	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
80:357	NULL
,	NULL
1987	NULL
14	NULL
.	NULL

You	NULL
M	NULL
,	NULL
Zhao	NULL
Z	NULL
:	NULL
Positive	NULL
effects	NULL
of	NULL
SH2	NULL
domain-containing	NULL
tyrosine	NULL
phosphatase	NULL
SHP-1	NULL
on	NULL
epidermal	NULL
growth	NULL
factor-	NULL
and	NULL
interferon-gamma-stimulated	NULL
activation	NULL
of	NULL
STAT	NULL
transcription	NULL
factors	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:23376	NULL
,	NULL
1997	NULL
15	NULL
.	NULL

Sui	NULL
X	NULL
,	NULL
Krantz	NULL
SB	NULL
,	NULL
Zhao	NULL
Z	NULL
:	NULL
Indentification	NULL
of	NULL
increased	NULL
protein	NULL
phosphatase	NULL
activity	NULL
in	NULL
polycythemia	NULL
vera	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

Blood	NULL
90:651	NULL
,	NULL
1997	NULL
16	NULL
.	NULL

Sawada	NULL
K	NULL
,	NULL
Krantz	NULL
SB	NULL
,	NULL
Sawyer	NULL
ST	NULL
,	NULL
Civin	NULL
CI	NULL
:	NULL
Quantitation	NULL
of	NULL
specific	NULL
binding	NULL
of	NULL
erythropoietin	NULL
in	NULL
Friend	NULL
virus-infected	NULL
erythroid	NULL
cells	NULL
.	NULL

J	NULL
Cell	NULL
Physiol	NULL
137:337	NULL
,	NULL
1988	NULL
17	NULL
.	NULL

Dai	NULL
CH	NULL
,	NULL
Krantz	NULL
SB	NULL
,	NULL
Koury	NULL
ST	NULL
,	NULL
Kolla	NULL
K	NULL
:	NULL
Polycythemia	NULL
vera	NULL
.	NULL

IV	NULL
.	NULL

Specific	NULL
binding	NULL
of	NULL
stem	NULL
cell	NULL
factor	NULL
to	NULL
normal	NULL
and	NULL
polycythemia	NULL
vera	NULL
highly	NULL
purified	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
88:497	NULL
,	NULL
1994	NULL
18	NULL
.	NULL

Jacobs-Helber	NULL
SM	NULL
,	NULL
Penta	NULL
K	NULL
,	NULL
Sun	NULL
Z	NULL
,	NULL
Lawson	NULL
A	NULL
,	NULL
Sawyer	NULL
ST	NULL
:	NULL
Distinct	NULL
signaling	NULL
from	NULL
stem	NULL
cell	NULL
factor	NULL
and	NULL
erythropoietin	NULL
in	NULL
HCD	NULL
57	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:6850	NULL
,	NULL
1997	NULL
19	NULL
.	NULL

Nishida	NULL
E	NULL
,	NULL
Gotoh	NULL
Y	NULL
:	NULL
The	NULL
MAP	NULL
kinase	NULL
cascade	NULL
is	NULL
essential	NULL
for	NULL
diverse	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

Trends	NULL
Biochem	NULL
Sci	NULL
18:128	NULL
,	NULL
1993	NULL
20	NULL
.	NULL

Davis	NULL
RJ	NULL
:	NULL
The	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
signal	NULL
transduction	NULL
pathway	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:14553	NULL
,	NULL
1993	NULL
21	NULL
.	NULL

Blumer	NULL
KJ	NULL
,	NULL
Johnson	NULL
GL	NULL
:	NULL
Diversity	NULL
in	NULL
function	NULL
and	NULL
regulation	NULL
of	NULL
MAP	NULL
kinase	NULL
pathways	NULL
.	NULL

Trends	NULL
Biochem	NULL
Sci	NULL
19:236	NULL
,	NULL
1994	NULL
22	NULL
.	NULL

Winston	NULL
LA	NULL
,	NULL
Hunter	NULL
T	NULL
:	NULL
Intracellular	NULL
signalling	NULL
:	NULL
Putting	NULL
JAKs	NULL
on	NULL
the	NULL
kinase	NULL
MAP	NULL
.	NULL

Curr	NULL
Biol	NULL
6:668	NULL
,	NULL
1996	NULL
23	NULL
.	NULL

Damnell	NULL
JE	NULL
Jr	NULL
:	NULL
STATs	NULL
and	NULL
gene	NULL
regulation	NULL
.	NULL

Science	NULL
277:1630	NULL
,	NULL
1997	NULL
24	NULL
.	NULL

Thle	NULL
JN	NULL
:	NULL
STATs	NULL
:	NULL
Signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcrip-tion	NULL
.	NULL

Cell	NULL
84:331	NULL
,	NULL
1996	NULL
25	NULL
.	NULL

Penta	NULL
K	NULL
,	NULL
Sawyer	NULL
ST	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
nuclear	NULL
translocation	NULL
,	NULL
and	NULL
DNA	NULL
binding	NULL
of	NULL
STAT1	NULL
and	NULL
STATS	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:31282	NULL
,	NULL
1995	NULL
26	NULL
.	NULL

Pallard	NULL
C	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Charon	NULL
M	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
:	NULL
Interleukin-3	NULL
,	NULL
erythropoietin	NULL
,	NULL
and	NULL
prolactin	NULL
activate	NULL
a	NULL
STAT5-like	NULL
factor	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:15942	NULL
,	NULL
1995	NULL
27	NULL
.	NULL

Klingmuller	NULL
U	NULL
,	NULL
Bergelson	NULL
S	NULL
,	NULL
Hsiao	NULL
JG	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Multiple	NULL
tyrosine	NULL
residues	NULL
in	NULL
the	NULL
cytosolic	NULL
domain	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
promote	NULL
activation	NULL
of	NULL
STATS	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
93:8324	NULL
,	NULL
1996	NULL
28	NULL
.	NULL

Gotoh	NULL
A	NULL
,	NULL
Takahira	NULL
H	NULL
,	NULL
Mantel	NULL
C	NULL
,	NULL
Litz-Jackson	NULL
S	NULL
,	NULL
Boswell	NULL
HS	NULL
,	NULL
Broxmeyer	NULL
HE	NULL
:	NULL
Steel	NULL
factor	NULL
induces	NULL
serine	NULL
phosphorylation	NULL
of	NULL
Stat3	NULL
in	NULL
human	NULL
growth	NULL
factor-dependent	NULL
myeloid	NULL
cell	NULL
lines	NULL
.	NULL

Blood	NULL
88:138	NULL
,	NULL
1996	NULL
29	NULL
.	NULL

Ryan	NULL
JJ	NULL
,	NULL
Huang	NULL
H	NULL
,	NULL
McReynolds	NULL
LJ	NULL
,	NULL
Shelburne	NULL
C	NULL
,	NULL
Hu-Li	NULL
J	NULL
,	NULL
Huff	NULL
TF	NULL
,	NULL
Paul	NULL
WE	NULL
:	NULL
Stem	NULL
cell	NULL
factor	NULL
activates	NULL
STAT-5	NULL
DNA	NULL
binding	NULL
in	NULL
IL-3-derived	NULL
bone	NULL
marrow	NULL
mast	NULL
cells	NULL
.	NULL

Exp	NULL
Hematol	NULL
25:357	NULL
,	NULL
1997	NULL
30	NULL
.	NULL

Sadowski	NULL
HB	NULL
,	NULL
Shuai	NULL
K	NULL
,	NULL
Darnell	NULL
JE	NULL
Jr	NULL
,	NULL
Gilman	NULL
MZ	NULL
:	NULL
A	NULL
common	NULL
nuclear	NULL
signal	NULL
transduction	NULL
pathway	NULL
activated	NULL
by	NULL
growth	NULL
factor	NULL
.	NULL

Science	NULL
261:1739	NULL
,	NULL
1993	NULL
31	NULL
.	NULL

Udy	NULL
CB	NULL
,	NULL
Towers	NULL
RP	NULL
,	NULL
Snell	NULL
RG	NULL
,	NULL
Wilkins	NULL
RJ	NULL
,	NULL
Park	NULL
S-H	NULL
,	NULL
Ram	NULL
PA	NULL
,	NULL
Waxman	NULL
DJ	NULL
,	NULL
Davey	NULL
HW	NULL
:	NULL
Requirement	NULL
of	NULL
STAT5b	NULL
for	NULL
sexual	NULL
dimor-phism	NULL
of	NULL
body	NULL
growth	NULL
rates	NULL
and	NULL
liver	NULL
gene	NULL
expression	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:7239	NULL
,	NULL
1997	NULL
32	NULL
.	NULL

Liu	NULL
X	NULL
,	NULL
Robinson	NULL
GW	NULL
,	NULL
Wagner	NULL
K-U	NULL
,	NULL
Garrett	NULL
L	NULL
,	NULL
Wynshaw-Boris	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

SYNERGISTIC	NULL
ACTIVATION	NULL
OF	NULL
MAPK	NULL
BY	NULL
EPO	NULL
AND	NULL
SCF	NULL
A	NULL
,	NULL
Hennighausen	NULL
L	NULL
:	NULL
Stats	NULL
is	NULL
mandatory	NULL
for	NULL
adult	NULL
mammary	NULL
gland	NULL
development	NULL
and	NULL
lactogenesis	NULL
.	NULL

Gene	NULL
Dev	NULL
11:179	NULL
,	NULL
1997	NULL
33	NULL
.	NULL

Xia	NULL
Z	NULL
,	NULL
Dickens	NULL
M	NULL
,	NULL
Raingeaud	NULL
J	NULL
,	NULL
Davis	NULL
RJ	NULL
,	NULL
Greenberg	NULL
ME	NULL
:	NULL
Opposing	NULL
effects	NULL
of	NULL
ERK	NULL
and	NULL
JNK-p38	NULL
MAP	NULL
kinases	NULL
on	NULL
apoptosis	NULL
.	NULL

Science	NULL
270:1326	NULL
,	NULL
1995	NULL
34	NULL
.	NULL

Marshall	NULL
CJ	NULL
:	NULL
Specificity	NULL
of	NULL
receptor	NULL
tyrosine	NULL
kinase	NULL
signaling	NULL
:	NULL
Transient	NULL
versus	NULL
sustained	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
activation	NULL
.	NULL

Cell	NULL
80:179	NULL
,	NULL
1995	NULL
35	NULL
.	NULL

Koury	NULL
MJ	NULL
,	NULL
Bondurant	NULL
MC	NULL
:	NULL
Erythropoietin	NULL
retards	NULL
DNA	NULL
breakdown	NULL
and	NULL
prevents	NULL
programmed	NULL
death	NULL
in	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

Science	NULL
248:378	NULL
,	NULL
1990	NULL
36	NULL
.	NULL

Knoepp	NULL
SM	NULL
,	NULL
Wisehart-Johnson	NULL
AE	NULL
,	NULL
Buse	NULL
MG	NULL
,	NULL
Bradshaw	NULL
CD	NULL
,	NULL
Ella	NULL
KM	NULL
,	NULL
Meier	NULL
KE	NULL
:	NULL
Synergistic	NULL
effects	NULL
of	NULL
insulin	NULL
and	NULL
phorbol	NULL
ester	NULL
on	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
in	NULL
Rat-l	NULL
HIR	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:1678	NULL
,	NULL
1996	NULL
37	NULL
.	NULL

Miyamoto	NULL
S	NULL
,	NULL
Teramoto	NULL
H	NULL
,	NULL
Gutkind	NULL
JS	NULL
,	NULL
Yamada	NULL
KM	NULL
:	NULL
Integrins	NULL
can	NULL
collaborate	NULL
with	NULL
growth	NULL
factors	NULL
for	NULL
phosphorylation	NULL
of	NULL
receptor	NULL
tyrosine	NULL
kinases	NULL
and	NULL
MAP	NULL
kinase	NULL
activation	NULL
:	NULL
Roles	NULL
of	NULL
integrin	NULL
aggregation	NULL
and	NULL
occupancy	NULL
of	NULL
receptors	NULL
.	NULL

J	NULL
Cell	NULL
Biol	NULL
135:1633	NULL
,	NULL
1996	NULL
38	NULL
.	NULL

Aronica	NULL
SM	NULL
,	NULL
Gingras	NULL
AC	NULL
,	NULL
Sonenberg	NULL
N	NULL
,	NULL
Cooper	NULL
S	NULL
,	NULL
Hague	NULL
N	NULL
,	NULL
Broxmeyer	NULL
HE	NULL
:	NULL
Macrophage	NULL
inflammatory	NULL
protein-lalpha	NULL
and	NULL
inter-feron-inducible	NULL
protein	NULL
10	NULL
inhibit	NULL
synergistically	NULL
induced	NULL
growth	NULL
factor	NULL
stimulation	NULL
of	NULL
MAP	NULL
kinase	NULL
activity	NULL
and	NULL
suppress	NULL
phosphorylation	NULL
of	NULL
eukaryotic	NULL
initiation	NULL
factor	NULL
4E	NULL
and	NULL
4E	NULL
binding	NULL
protein	NULL
1	NULL
.	NULL

Blood	NULL
89:3582	NULL
,	NULL
1997	NULL
1149	NULL
39	NULL
.	NULL

O'Farrell	NULL
AM	NULL
,	NULL
Ichihara	NULL
M	NULL
,	NULL
Mui	NULL
AL	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
Signaling	NULL
pathways	NULL
activated	NULL
in	NULL
a	NULL
unique	NULL
mast	NULL
cell	NULL
line	NULL
where	NULL
interleukin-3	NULL
supports	NULL
survival	NULL
and	NULL
stem	NULL
cell	NULL
factor	NULL
is	NULL
required	NULL
for	NULL
a	NULL
proliferative	NULL
response	NULL
.	NULL

Blood	NULL
87:3655	NULL
,	NULL
1996	NULL
40	NULL
.	NULL

Lev	NULL
S	NULL
,	NULL
Blechman	NULL
JM	NULL
,	NULL
Givol	NULL
D	NULL
,	NULL
Yarden	NULL
Y	NULL
:	NULL
Steel	NULL
factor	NULL
and	NULL
c-kit	NULL
protooncogene	NULL
:	NULL
Genetic	NULL
lesssons	NULL
in	NULL
signal	NULL
transduction	NULL
.	NULL

Crit	NULL
Rev	NULL
Oncog	NULL
5:141	NULL
,	NULL
1994	NULL
41	NULL
.	NULL

Miura	NULL
Y	NULL
,	NULL
Miura	NULL
O	NULL
,	NULL
Ihle	NULL
JN	NULL
,	NULL
Aoki	NULL
N	NULL
:	NULL
Activation	NULL
of	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathway	NULL
by	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:29962	NULL
,	NULL
1994	NULL
42	NULL
.	NULL

Damen	NULL
JE	NULL
,	NULL
Liu	NULL
L	NULL
,	NULL
Cutler	NULL
RL	NULL
,	NULL
Krystal	NULL
G	NULL
:	NULL
Erythropoietin	NULL
stimulates	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
She	NULL
and	NULL
its	NULL
association	NULL
with	NULL
Grb2	NULL
and	NULL
a	NULL
145-Kd	NULL
tyrosine	NULL
phosphorylated	NULL
protein	NULL
.	NULL

Blood	NULL
82:2296	NULL
,	NULL
1993	NULL
43	NULL
.	NULL

Verdier	NULL
F	NULL
,	NULL
Chrétien	NULL
S	NULL
,	NULL
Billat	NULL
C	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Lacombe	NULL
C	NULL
,	NULL
Mayeux	NULL
P	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
insulin	NULL
receptor	NULL
substrate-2	NULL
.	NULL

An	NULL
alternate	NULL
pathway	NULL
for	NULL
erythropoietin-induced	NULL
phosphatidylinosito	NULL
!	NULL

3-kinase	NULL
activation	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272	NULL
:	NULL
26173	NULL
,	NULL
1997	NULL
44	NULL
.	NULL

Klingmuller	NULL
U	NULL
,	NULL
Wu	NULL
H	NULL
,	NULL
Hsiao	NULL
JG	NULL
,	NULL
Toker	NULL
A	NULL
,	NULL
Duckworth	NULL
BC	NULL
,	NULL
Cantley	NULL
LC	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Identification	NULL
of	NULL
a	NULL
novel	NULL
pathway	NULL
important	NULL
for	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
primary	NULL
erythroid	NULL
progenitors	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:3016	NULL
,	NULL
1997	NULL
45	NULL
.	NULL

Barber	NULL
DL	NULL
,	NULL
Corless	NULL
CN	NULL
,	NULL
Xia	NULL
K	NULL
,	NULL
Roberts	NULL
TM	NULL
,	NULL
D'Andrea	NULL
AD	NULL
:	NULL
Erythropoietin	NULL
activates	NULL
Rafl	NULL
by	NULL
an	NULL
Shc-independent	NULL
pathway	NULL
in	NULL
CTLL-EPO-R	NULL
cells	NULL
.	NULL

Blood	NULL
89:55	NULL
,	NULL
1997	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blOOd	NULL
1998	NULL
92	NULL
:	NULL
1142-1149	NULL
Synergistic	NULL
Activation	NULL
of	NULL
MAP	NULL
Kinase	NULL
(	NULL
ERK1/2	NULL
)	NULL
by	NULL
Erythropoietin	NULL
and	NULL
Stem	NULL
Cell	NULL
Factor	NULL
Is	NULL
Essential	NULL
for	NULL
Expanded	NULL
Erythropoiesis	NULL
Xingwei	NULL
Sui	NULL
,	NULL
Sanford	NULL
B.	NULL
Krantz	NULL
,	NULL
Min	NULL
You	NULL
and	NULL
Zhizhuang	NULL
Zhao	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
©1004	NULL
@	NULL
207	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/92/4/1142.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

